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Abstract 
A major obstacle to neural regeneration after injury in the central nervous system 
(CNS) is the environment encountered by injured axons.  This environment is inhibitory 
due to proteins expressed by the CNS myelin as well as molecules present in the glial 
scar. Experimental results have implicated chondroitin sulfate proteoglycans (CSPGs) as 
major inhibitors of axonal regeneration after CNS injury, but until recently, the 
mechanisms of this inhibition were not well understood. Furthermore, the complex nature 
of the chondroitin sulfate (CS) chains made it difficult to study their contribution to 
CSPG function. This thesis describes a specific carbohydrate epitope, CS-E, that is 
primarily responsible for the inhibition of CNS axonal regrowth in the presence of 
CSPGs.  We show that removal or blocking of the CS-E motif via genetic elimination of 
the enzyme responsible for generating CS-E or a monoclonal antibody that binds 
specifically to the CS-E motif significantly reduces the inhibitory activity of CSPGs on 
axon growth. Furthermore, we show that CS-E functions as a protein recognition element 
to engage receptors, including the transmembrane protein tyrosine phosphatase PTPσ, 
which had been previously established to be a receptor for CSPGs. Finally, we show that 
the protein tyrosine kinase receptor EphA4 is a novel receptor for the CS-E motif, and as 
with PTPσ, neurons deficient in EphA4 exhibit reduced inhibition by CS-E. Our results 
demonstrate that a specific sugar epitope within chondroitin sulfate polysaccharides 
directs important physiological processes, and establish the importance of the chemical 
structure of CS chains in modulating the activity of CSPGs in vivo. The identification of 
receptors that mediate the inhibitory effect of CS-E advances our understanding of the 
iv 
mechanisms of axon regeneration following injury to the CNS when CS-E expression is 
upregulated. These findings provide us with the opportunity to develop therapies for the 
recovery of axonal outgrowth after damage to the nervous system, which in conjunction 
with blocking approaches targeting the CS motif, can provide a powerful strategy for 
allowing recovery after injury to the CNS. 
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Chapter 1: Introduction to Chondroitin Sulfate and 
Inhibition in the Central Nervous System 
 
Inhibition in the CNS 
In the adult central nervous system (CNS), axons have very little ability to 
regenerate after injury. In contrast, neurons in the peripheral nervous system (PNS) and the 
embryonic CNS can regenerate, and this difference is explained by both the reduced 
capability for growth of mature neurons, and the presence of inhibitory molecules in the 
adult CNS.1-5 A possible reason for the existence of these inhibitory molecules is that they 
are critical for pathfinding and axon guidance in the developing nervous system, and only 
present a problem in the mature organism after injury.6 The chondroitin sulfate 
proteoglycans (CSPGs) are one of the main inhibitory components of the CNS, and can be 
found in the glial scar that forms after neuronal damage and acts as a barrier to axon 
regeneration.6-8 The other inhibitory components are the members of a group of molecules 
known as the myelin-associated inhibitors (MAIs), which are expressed on the surface of 
oligodendrocytes. 
It has long been known that CNS myelin inhibits neuronal growth, while PNS 
myelin does not have this property.9 In vitro investigations of CNS myelin led to the 
isolation and cloning of the reticulon protein Nogo-A, which was found to be highly 
inhibitory to neuronal growth in culture.10 Later studies identified myelin-associated 
glycoprotein (MAG) and oligodendrocyte myelin glycoprotein (OMgp), two additional 
inhibitory proteins that, like Nogo-A, are expressed by oligodendrocytes, and are strongly 
inhibitory to neuron regeneration.11-13 These three proteins serve as independent ligands for 
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a common receptor complex, and all ligands bind to the Nogo receptor NgR,13-15 providing 
an attractive target for blocking strategies. A more thorough discussion of these proteins 
and the receptors that mediate their activity can be found in Appendix 1. Findings by our 
lab and others have determined that there is overlap between the cellular mechanisms 
underlying the inhibitory effects of these two groups of molecules, and further research will 
provide a clearer picture of the interactions and interplay of these inhibitors. This thesis 
describes what we have discovered about both groups of molecules, with primary emphasis 
on the CSPGs. 
CS Biosynthesis and Regulation 
CSPGs, along with HSPGs, DSPGs, and KSPGs (chondroitin, heparan, dermatan, 
and keratan sulfate proteoglycans, respectively) are a type of protein with covalently 
attached carbohydrate chains known as glycosaminoglycans (GAGs).7 These 
proteoglycans can be found in the extracellular matrix or expressed on the cell surface of 
many types of cells. The GAG chains on these proteins are comprised of linear chains of 
repeated disaccharide subunits, which differ among the GAG types (Figure 1.1). 
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Figure 1.1. Representative classes of glycosaminoglycans, with potential sites of sulfation indicated. 
R=SO3- or H; R1 = SO3-, H, or Ac; n= ~40-200. 
 
The work described in this thesis focuses on the CSPGs and their interactions 
with protein receptors. Chondroitin sulfate (CS) is synthesized by the cell in the 
endoplasmic reticulum and the Golgi apparatus. This synthesis begins with the addition 
to the target protein of a tetrasaccharide linkage region, composed of xylose, two 
galactose molecules, and glucuronic acid. Xylose is first attached to a serine residue of 
the target protein via a xylosyl transferase, and this occurs in the endoplasmic reticulum, 
while the remaining sugars are attached in the Golgi apparatus.16 Additional 
modifications can also take place here, and the glycosylated protein is then transported to 
the cell membrane via the trans-Golgi network. 
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Figure 1.2. CS polysaccharides are composed of disaccharide repeating units of D-glucuronic acid 
(GlcA) and N-acetyl-D-galactosamine (GalNAc).  The sugar hydroxyls are variably sulfated to give 
rise to diverse sulfation patterns.  Chemical structures of major sulfation motifs found in the 
mammalian nervous system: CS-A (GlcA-4SGalNAc), CS-C (GlcA-6SGalNAc), CS-D (2SGlcA-
6SGalNAc) and CS-E (GlcA-4S, 6SGalNAc).  n = 20-200. 
 
CS is comprised of an unbranched chain of alternating glucuronic acid (GlcA) and 
N-acetylgalactosamine (GalNAc). The CS chain is elongated by CS polymerases, and can 
range in length from 20-200 disaccharide units.17-19 During elongation, the disaccharide 
motifs of CS can be sulfated in a variety of ways, and these sulfate groups are introduced 
via the CS sulfotransferases (STs) in the Golgi apparatus.16 The most common CS motifs 
are shown in Figure 1.2. There have been seven sulfotransferases identified to date: three 
isoforms of C4ST,20, 21 two isoforms of C6ST,22, 23 a uronyl-2-sulfotransferase, which 
converts CS-C to CS-D,24 and GalNAc4S-6ST, which converts CS-A to CS-E.25 The two 
most common CS motifs, CS-A and CS-C, are generated by the sulfation of the C4 and C6 
hydroxyl of GalNAc, respectively.16 The CS-C motif can be further modified by the 
addition of a sulfate group to the C2 hydroxyl of GlcA to produce CS-D, while the CS-A 
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motif can be modified by the addition of a second sulfate group to the C4 hydroxyl of 
GalNAc to form CS-E (Figure 1.3).   
Different sulfated motifs of CS occur in specific brain regions and tracts, and are 
expressed in an age-dependent manner, supporting the notion of CS serving as a cue or 
boundary for axon guidance.26, 27 This is correlated with the expression of sulfotransferases 
in specific brain regions, with several of these enzymes being highly expressed in the 
embryo, with less expression in the neonatal brain.28 The expression of CS is important for 
the guidance of axons in the development of tracts, and a loss of CS results in aberrant 
growth of axons in the embryonic nervous system and the retina.29, 30 
 
Figure 1.3. Biosynthesis of chondroitin sulfate by the sulfotransferases. 
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Since it is known that CSPGs are a major contributor to the inhibition of 
regeneration after injury, various groups have investigated the time-dependent upregulation 
of CSPGs after a lesion is introduced. Increased immunostaining of the CSPGs neurocan, 
NG2, brevican, and versican is observed after injury to the spinal cord, and peak detection 
of this increase occurs rapidly, within a week or less.31-33 In some cases, increased 
expression is observed within 24 hours.31 Increased expression of neurocan and versican 
has also been observed in injuries to the cortex,34, 35 again with peak increases observed 
within a week or less. These results show that certain types of CSPGs become more 
prevalent after injury, and these CSPGs may prove to be particularly inhibitory. It is known 
that the growth inhibition effect is due mostly or completely to the CS chains of 
proteoglycans, rather than the protein cores.36, 37 Therefore, some groups have investigated 
whether changes occur to the CS side chains after injury.  One group studied the ratio of 
different CS motifs in uninjured or injured mouse cortex. In uninjured animals, CS-A was 
the dominant motif, but became significantly reduced after injury. On the other hand, CS-C 
became more prevalent, and the CS-D and CS-E motifs were present in observable 
amounts, which was not the case prior to injury.38 This difference in motif abundance is 
likely due to the differential expression of sulfotransferases, the expression of which has 
been shown to be modified after injury.27  
The work described in this thesis shows that the CS-E motif is one of the main 
contributors to neuron outgrowth inhibition after injury to the CNS, and is the element 
present on CSPGs responsible for their inhibitory effect. Work by our collaborators has 
shown that CS-E is strongly and rapidly upregulated after injury; in the optic nerve, CS-E 
expression increased soon after injury, with intense staining visible within 24 hours (see 
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Chapter 3). Furthermore, blocking of CS-E via a monoclonal antibody reversed the 
inhibitory effect. Subsequent research by others has supported our finding: recently, it was 
shown that localized upregulation of GalNAc46ST occurs in the cortex after lesioning. This 
study also found that astrocytes that had been treated with siRNA to downregulate the 
expression of C4ST or GalNAc46ST, thus reducing or eliminating the presence of CS-A 
and CS-E or CS-E alone, respectively, resulted in astrocytes that were less inhibitory to 
cortical neurite outgrowth.39 Taken together, these results suggest that the CS-E motif 
becomes more prevalent concurrent with the upregulation of CSPGs, and provides most if 
not all of the inhibitory effect of CSPGs. 
The CS-E motif 
The CS-E motif has been shown to be widely expressed in the developing nervous 
system and in the cerebellum and olfactory bulb of postnatal mice.40 In certain contexts, 
this CS motif promotes the growth of neurons.41, 42 This effect was first observed in 
embryonic hippocampal neurons, the growth of which is also increased by the CS-D motif, 
although to a lesser degree than that seen with CS-E. 41 This growth-promoting effect was 
further confirmed by our group, which used a chemically synthesized CS-E tetrasaccharide 
to demonstrate the result, eliminating the possibility of mixed disaccharide subunits being 
responsible for the effect.42  The growth-promoting effect was found to be due to the 
protein-binding properties unique to CS-E, as certain growth factors were shown to bind 
specifically to this motif, and not to other CS motifs. This selective binding provides a 
mechanism in which CS-E is able to increase the local concentration of growth factors 
present in vivo, and thereby increase neuronal growth.43, 44  
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As mentioned previously, in other contexts CS-E is potently inhibitory, and 
overcoming this inhibition is critical for regeneration after injury. In the postnatal nervous 
system, CS-E is typically not present in measurable amounts, and is only observed after 
injury.38 In contrast to the embryonic nervous system, in which CS-E recruits factors to 
stimulate growth, CS-E that is upregulated after injury engages protein receptors on the 
surface of neurons to transmit downstream inhibitory signaling. The work described in this 
thesis shows the specific binding partners of CS-E that we have discovered, and how the 
inhibitory effect can be eliminated by blocking the CS-E motif and thus disrupting receptor 
binding.  
A valuable tool for elucidating the role of CS-E is mice that are deficient in 
GalNAc4S-6ST, the enzyme that catalyzes the formation of CS-E. These knockout animals 
are born healthy and fertile, and have no obvious physical defects. One possible effect is a 
decreased litter size in homozygous crosses that perhaps suggests some degree of 
embryonic lethality, although this has not been systematically studied.43  Recent results 
from our group show that axon pathfinding is altered in these embryos, with ectopic retinal 
axon terminations in the superior colliculus (C. Rogers, unpublished results). Furthermore, 
it is expected that these animals will exhibit enhanced recovery after spinal cord injury, as 
the CS-E motif is a major contributor to this inhibition (see Chapter 3). These mice that are 
genetically deficient in CS-E provide the opportunity to study a system that is completely 
devoid of the motif, giving valuable insights into the functions for which CS-E is essential. 
However, there are some drawbacks to using these mice for studying regeneration of 
growth after injury. By genetically removing the GalNAc4S-6ST enzyme, we may 
introduce subtle variations into the CS chains, or cause changes to the developing animal 
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that obfuscate recovery studies. Furthermore, removing the CS-E motif may influence the 
expression or localization of other molecules that are involved in inhibition and growth 
promotion. 
Interestingly, the group that generated the knockout animals observed that the mast 
cells of CS-E-deficient mice had reduced protease activity. Mast cells are inflammation-
mediating cells of the immune system, and can be found in the adult CNS localized around 
lesion sites.44 These cells have been found to contain intracellular CS-E,45, 46 and could be 
responsible for delivering CS-E to the injury site. Any subsequent release of CS-E, along 
with stimulation of the immune system, could contribute to the lack of regeneration. The 
reduced protease activity observed in the knockout animals, along with the lack of CS-E, 
could together contribute to enhance regeneration in these animals. On the other hand, there 
could be as-yet-unobserved effects in the immune systems that will prove to be detrimental 
to injury recovery; furthermore, mast cells are known to produce factors with regenerative 
properties,47 so it is unclear what the dominant effect will be. Future studies with these 
animals will more clearly describe the role of CS-E in development and in recovery after 
lesions to the CNS. 
CS Receptors 
Before the discovery of specific proteins that interact with and mediate the 
inhibitory effects of CSPGs,48-50 there were several observations that implicated a receptor-
based mechanism. An early clue was the finding that CSPGs elevate cytoplasmic Ca2+ 
levels,51 and this effect was associated with growth inhibition and the reorganization of 
growth cone actin. It has been known for some time that like the myelin inhibitors, CSPGs 
induce the activation of RhoA.52-55 Activation of this GTPase leads to growth cone collapse 
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and the retraction of neurites via the downstream destabilization of the actin cytoskeleton,54 
via ROCK1 (Rho-associated, coiled-coil containing protein kinase 1).56 In another 
convergence of signaling, both the myelin inhibitors and CSPGs induce the activation of 
protein kinase C (PKC).57 This activation is thought to be necessary for RhoA activation, as 
PKC inhibition eliminates the activation of Rho by either CSPGs or the myelin inhibitors. 
It was also discovered that CSPGs activate the mitogen-activated protein kinase (MAPK) 
pathway via the epidermal growth factor receptor (EGFR). It was observed that a MAPK 
inhibitor or EGFR inhibitor blocked the effects of CSPGs on neurite outgrowth.58 
Furthermore, it was found that MAPK was phosphorylated in response to CSPGs, and this 
phosphorylation was lost upon the inhibition of EGFR. EGFR was also found to be 
phosphorylated in response to CSPGs, and these phosphorylated sites are known to be 
involved in PKC signaling, further establishing that PKC activation induced by the CSPGs 
is dependent on the activation of EGFR.58 This activation of EGFR is thought to occur via 
trans-activation, in which other signaling pathways activate the receptor and its 
downstream targets.59 
The first discovered receptor that directly interacts with CSPGs and becomes 
activated in response was the protein tyrosine phosphatase receptor PTPσ.48 This protein is 
a member of the leukocyte antigen-related (LAR) receptor family, and PTPσ as well as 
other members of this family had previously been identified as receptors for heparan sulfate 
proteoglycans.60-62 Subsequent work by our group showed that the CS-E motif is 
responsible for mediating the interaction between PTPσ and CSPGs, and that neurons 
deficient in PTPσ are less inhibited by CS-E.56 Recent work has shown that HS and CS 
share a common binding site on PTPσ, and their differing effects on cell growth (promoting 
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and inhibiting, respectively) may be dependent on the nature of the GAG chain, and 
whether or not binding to the receptor allows growth-promoting receptor clusters.63 PTPσ 
contains intracellular phosphatase domains that interact with the guanine nucleotide 
exchange factor Trio, a protein that activates the Rho family of small GTPases,64, 65 
providing evidence of further convergence at RhoA.  
Another phosphatase receptor that is related to PTPσ, the leukocyte common 
antigen-related phosphatase receptor (LAR), was next identified as a receptor that directly 
engages the CSPGs to inhibit neuron growth.66 Deletion of this receptor led to the 
elimination of RhoA activation in response to CSPGs, showing the role of this molecule in 
the downstream signaling of LAR. Similar results were seen with the protein kinase Akt, 
which was found to be dephosphorylated in response to CSPGs. Removal of LAR led to 
sustained phosphorylation of this kinase upon treatment with CSPGs, further elucidating 
the downstream effects of CSPGs. 
It was recently found that CSPGs engage the Nogo receptor isoforms NgR1 and 
NgR3, representing a convergence in signaling for CSPGs and the myelin inhibitory 
proteins.50 Additionally, it was found that removing both NgR and PTPσ resulted in even 
greater reduction of inhibition by CSPGs, demonstrating that the inhibitory effect is exerted 
on multiple receptors simultaneously. Our lab has found that NgR binds to CS-E 
polysaccharides with remarkably high affinity and specificity, with at least two 
independent, high-affinity NgR binding sites within CS-E polysaccharides (unpublished 
data; see Appendix 1). No binding was seen with other CS motifs, once again showing that 
CS-E is the critical binding and functional element with CS chains of CSPGs for receptor 
activation. 
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Finally, the guidance molecule semaphorin 5A (Sema5A) has been shown to 
modulate the effects of CSPGs.67 As in the case of PTPσ, Sema5A interacts with both 
CSPGs and HSPGs. It was found that when growth cones of expanding axons encounter 
Sema5A, HS or CS present on the axon surface were responsible for determining whether 
Sema5a was attractive or repellant, respectively. This suggests that HSPGs and CSPGs 
form a functional receptor complex with unidentified Sema5A receptors, and GAGs on the 
neuronal surface could be involved in the modulation of growth of these neurons. 
It was also shown that CSPGs could inhibit growth by disruption of the adhesion 
between neurons and their substrate. One group found that CSPGs inhibited axon growth 
through the inactivation of the attachment-mediating receptor integrin on substrates of 
laminin, demonstrating the importance of cell adhesion molecules in neuronal growth.68 
Future studies will continue to elucidate how these multiple receptors interact with the 
various molecules already implicated in CSPG-mediated inhibition of growth. 
Combinations of inhibitory strategies against these molecules may completely eliminate 
CSPG suppression of growth in the CNS to achieve axonal regeneration after injury in vivo. 
Overcoming Inhibition 
Since the discovery of the myelin-associated inhibitors, strategies have been 
devised to overcome the inhibitory effect of these proteins. One technique for overcoming 
inhibition of regeneration after injury is by blocking the inhibitory molecules with 
antibodies specific to either the ligand or receptor, effectively preventing them from 
exerting their effect. It was found that antibodies against the myelin inhibitors are able to 
increase neurite outgrowth in response to myelin in vitro, and to improve recovery after 
injuries to the nervous system in vivo.69 
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In particular, antibodies against Nogo-A have been shown to increase regeneration 
in several injury models. Rats had lesions to their spinal cords administered, after which an 
antibody against Nogo was delivered immediately and continuously for two weeks. 
Animals receiving this antibody showed increased functional recovery compared to control, 
and were shown to have more axons extending past the injury site.70 In addition to 
problems with movement, other issues such as muscle spasms are observed with less severe 
injuries to the spinal cord. The Nogo antibody was also able to relieve this effect.71 It is 
hoped that this treatment strategy can be applied to humans with injuries to the spinal cord, 
and efforts are underway to make this a viable treatment strategy.72 Studies have shown 
that the effect of the antibody treatment is observed when administered immediately or 
within one week after injury. Treatment administered two weeks after injury does not give 
the beneficial effect.73 This is likely related to the timing of upregulation of inhibitory 
molecules, as Nogo expression increases within days after injury to the spinal cord.74 
Similar results were found in cortical injury models, with improvements in both axonal 
projections and test of skilled limb functions.75, 76 In another study, a small peptide, which 
was identified as blocking the interaction between Nogo and NgR, was administered after 
injury, and was found to found to improve functional recovery in spinal cord injury 
models.77  
In spite of these promising results, it has been found that genetically deleting either 
NgR or p75, a co-receptor that is necessary for the downstream signaling of NgR, does not 
result in significant recovery after spinal cord injury.78 Similarly, genetic deletion of all 
Nogo isoforms does not result in enhanced regeneration after injury.79 One possible 
explanation is that the study with NgR did not account for all isoforms of NgR, and at least 
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two of the isoforms have been shown to be critical for the mediation of inhibition by 
CSPGs, which could also apply to the myelin inhibitors.50 Furthermore, it has been shown 
that the p75 co-receptor critical for NgR activity can be replaced by another functional 
equivalent,80 explaining the lack of effect in p75-deficient animals. Finally, other groups 
have speculated that the blocking agents used to neutralize Nogo and its receptor may 
themselves have some additional growth-promoting effects beyond their specific blocking 
capability, or that genetically deleting Nogo or its receptors could result in neurons that are 
less likely to regenerate based on other functions of these proteins.81  
Another method of improving recovery after injury is to stimulate the intrinsic 
growth capability of the neurons. One such means of doing this is via the second messenger 
molecule cyclic adenosine monophosphate (cAMP). Endogenous cAMP is present in much 
higher levels in young neurons compared to older neurons, and this level correlates with the 
neurons’ ability to regenerate.82 Exogenous cAMP has been shown to increase survival of 
neurons,83 and to block the effects of myelin-associated inhibitors.84 Furthermore, it has 
been previously shown that the application of cAMP analogs (CPT-cAMP) can increase 
regeneration in the injured optic nerve or spinal cord.85, 86 
As with the myelin inhibitors, an antibody against inhibitory CS motifs could 
potentially help to overcome inhibition by blocking the motifs and preventing them from 
interacting with their receptor proteins. Previously, a variety of methods have been used to 
generate antibodies against chondroitin sulfate. The antigens used to generate antibodies in 
the past have included proteoglycans, glycoproteins, and CSPGs, all derived from natural 
sources.87-93 In these cases, the CS antigens have a mixture of sulfation motifs present, 
making it difficult to determine which motifs are being detected, and which motifs are 
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present on a particular sample being analyzed by antibody for immunostaining studies.  
Analysis of the specificity of these antibodies usually has occurred via competition assays 
with known standards.87-91, 94, 95 The Hsieh-Wilson lab has generated and characterized 
mouse monoclonal antibodies that were raised against CS tetrasaccharides synthesized by 
the lab.96 With these antibodies, specific detection of natural polysaccharides bearing the 
relevant motif is possible, allowing the study of endogenous CS motif expression, and the 
blocking of specific motifs in vitro and in vivo (See Chapter 3).  
 
Conclusions 
Chondroitin sulfate has been shown to serve many diverse roles in the developing 
and mature organism, but its role in inhibiting growth after injury is still emerging. After 
injury to the adult CNS, axon regeneration is inhibited, due in large part to the effects of 
CSPGs present in the glial scar. CSPGs can interact with a variety of cell-surface molecules 
to exert an inhibitory effect, and this effect is dependent upon the complex CS chains of 
CSPGs. The work in this thesis shows that the effects of CSPGs are due to the CS-E motif, 
which itself it highly inhibitory and is the critical element for binding to receptors and for 
inducing downstream inhibition of growth. This work also describes our efforts at finding 
novel proteins that interact with CS-E and thus serve as CSPG receptors. Elucidating the 
complex mechanisms of neuronal inhibition in the CNS will allow these interactions to be 
blocked or attenuated, such that regeneration in the CNS can be achieved. 
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Chapter 2: Chondroitin Sulfate Proteoglycans and 
Protein Binding∗†
 
 
Introduction 
Glycosaminoglycans are sulfated polysaccharides that play important roles in fundamental 
biological processes, such as cell division, viral invasion, cancer and neuroregeneration.  
The multivalent presentation of multiple glycosaminoglycan chains on proteoglycan 
scaffolds may profoundly influence their interactions with proteins and subsequent 
biological activity. Carbohydrates possess greater structural diversity than either nucleic 
acids or proteins.  Although they participate in a wide range of critical processes and 
alterations in their structure have been linked to a number of human diseases, they remain 
under-explored targets for chemical biology and pharmaceutical chemistry.  We have 
embarked on a program to study a large class of sulfated polysaccharides known as 
glycosaminoglycans, with the goals of understanding their structure-function relationships 
and gaining insight into the molecular mechanisms underlying their biological activity.   
 
                                                 
∗ Synthesis of all of the chondroitin sulfate glycopolymers was carried out by Dr. Song-Gil 
Lee, a former postdoctoral scholar in the Hsieh-Wilson laboratory. 
† Portions of this chapter were taken from Lee, S.-G.; Brown, J.M.; Rogers, C. J.; Matson, 
J. B.; Krishnamurthy, C.; Rawat, Manish; Hsieh-Wilson, L.C. End-Functionalized 
Glycopolymers as Mimetics of Chondroitin Sulfate Proteoglycans. Chem. Sci. 2010, 1, 
322 – 325. 
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Figure 2.1. Representative classes of glycosaminoglycans, with potential sites of sulfation indicated. 
R=SO3- or H; R1 = SO3-, H, or Ac; n= ~40-200. 
 
 
Figure 2.2. CS polysaccharides are composed of 20-200 units of the repeating disaccharide D-
glucuronic acid (GlcA) and N-acetyl-D-galactosamine (GalNAc).  The sugar hydroxyls are variably 
sulfated to give rise to diverse sulfation patterns.  Chemical structures of major sulfation motifs 
found in the mammalian nervous system: CS-A (GlcA-4SGalNAc), CS-C (GlcA-6SGalNAc) and CS-
E (GlcA-4S, 6SGalNAc).  n = 20-200. 
 
Glycosaminoglycans (GAGs) are polymers, composed of 10–200 repeating sulfated 
disaccharide units (Figure 2.1).1-3  They contain regions of high and low sulfation,4, 5 with 
highly sulfated regions serving as binding sites for proteins,6-10 and these interactions 
endow GAGs with the ability to regulate essential processes such as cell division, viral 
invasion, blood coagulation and neuronal regeneration.1, 2, 6, 11-13 The CS-A, CS-C and CS-E 
disaccharides represent major sulfation motifs in the mammalian CNS (Figure 2.2), and our 
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lab has previously shown that the CS-E motif in particular can serve as a recognition unit 
for proteins such as growth factors, thus regulating cellular growth.14 The CS-E motif can 
also act as a ligand to engage receptors and trigger downstream cellular events (see 
Chapters 3 and 4). 
GAGs are covalently attached to various proteoglycan proteins, with some 
proteoglycans bearing as many as 100 sugar chains (Figure 2.3).15  It has been established 
using synthetic glycopolymers and oligosaccharides for other systems that the relative 
position and density of sugars can impact the avidity and specificity of glycan-protein 
interactions.16-20  However, despite these advancements, the role of the multivalent 
architecture found in native GAG structures has remained largely unexplored. 
  
 
Figure 2.3. Schematic representation of a proteoglycan, which typically consists of multiple GAG 
chains attached to a protein core (left); Biotin end-functionalized ROMP polymers as mimetics of CS 
proteoglycans. n = ~80-280 (right). 
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Results  
 To mimic the orientation of the sugar chains on proteoglycans, we designed a CS  
glycopolymer, which has an end-functionalized biotin moiety to achieve the desired 
orientation of the pendant sugars and to facilitate attachment of the polymer to surfaces 
(Figure 2.4).  We chose a norbornene-based backbone to allow for multivalent display of  
 
 
Figure 2.4. Biotin End-Functionalized CS Glycopolymers. 
 
the sugar chains at defined, chemically controlled intervals and to confer a degree of 
rigidity to the structure.  Previous studies in our laboratory have demonstrated that 
glycopolymers containing complex, highly anionic di- and tetrasaccharides can be 
generated using ring-opening metathesis polymerization (ROMP) chemistry, although 
more flexible cis-cyclooctene monomers were employed.21 In addition to increasing the 
structural rigidity of the resultant polymer, norbornene-based monomers would have the 
advantage of enabling access to block copolymers for controlling the sulfation motifs 
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between GAG chains. We next investigated end-functionalization of the glycopolymers 
with a biotin moiety. Addition of the biotin terminating agent to the reaction mixture after 
completion of the living polymerization resulted in the desired end-capping of the 
glycopolymer. 
 
 
 
Figure 2.5. Depiction of the microarray printing robot adding carbohydrate solutions to the glass 
slide surface (left). A representative experimental slide is shown on the right, where areas of 
fluorescence indicate protein binding to the carbohydrates on the surface after the addition of a 
fluorescent antibody specific to the protein being investigated. 
 
To explore the ability of the glycopolymers to interact with proteins of interest, the 
unsulfated and CS-E sulfated biotin glycopolymers (Figure 2.4) were attached to 
microarray surfaces.  A high-precision contact-printing robot was used to deliver nanoliter 
volumes of the biotin-labeled glycopolymers to streptavidin-coated slides, yielding spots 
approximately 200 µm in diameter (Figure 2.5).  We examined the binding of monoclonal 
antibodies 2D11 and 2D5, which are selective for the CS-E and CS-C sulfation motifs, 
respectively.7, 14  The microarrays were incubated with each antibody (70 nM), and protein 
binding was visualized using a secondary Cy3-conjugated goat anti-mouse antibody.   
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Figure 2.6. Top: Binding of the CS-E mAb (left) and the CS-C mAb (right) to unsulfated and CS-E 
sulfated polymer. A representative portion of the array is shown (inset). The CS-C mAb did not bind 
to either polymer on the array; Bottom: Representative portion of the microarray, illustrating spot 
morphology and fluorescence intensity after incubation with the CS-E antibody.  Note that only a 
small portion of the microarray is shown.  The panel on the right indicates the corresponding 
polymers and their concentrations for each spot shown. Values are in μM. E = CS-E sulfated 
polymer, U = Unsulfated polymer.   
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Figure 2.7. Relative binding of GDNF to glycopolymers on the biotinylated polymer microarray. 
 
Antibody 2D11 bound selectively to the CS-E sulfated glycopolymer and showed no 
detectable binding to the unsulfated glycopolymer (Figure 2.6).   
Moreover, no binding of the CS-C antibody 2D5 to either glycopolymer was 
observed, consistent with the selective recognition of specific sulfated epitopes.  We also 
examined the binding of several growth factors, including glial cell-derived neurotrophic 
factor (GDNF), a growth factor important for the survival and differentiation of 
dopaminergic neurons.22, 23 Although the binding of GDNF to a highly sulfated mixture of 
chondroitin and dermatan sulfate chains has been studied,8 its ability to recognize 
homogeneous, well-defined CS structures has not been explored.  Significant binding of 
GDNF to the CS-E sulfated glycopolymer, but not the unsulfated glycopolymer, was 
observed (Figure 2.7), indicating a clear preference of GDNF for the sulfated sugar epitope. 
Finally, we investigated whether the end-functionalized glycopolymers could be 
used to facilitate quantitative, real-time analysis of GAG-protein interactions using surface 
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plasmon resonance (SPR).  The unsulfated and CS-E sulfated glycopolymers were 
immobilized on streptavidin-conjugated CM5 sensor chips at low density (RL ≈ 25 RU) 
 
 
Figure 2.8. Top: Surface plasmon resonance of GDNF binding to CS glycopolymers. GDNF at 
varying concentrations (2, 1, and 0.5 nM) binds to the CS-E sulfated glycopolymer (red), but not the 
unsulfated polymer (black); Bottom: The dissociation constant (KD) for the interaction between the 
CS-E sulfated polymer and GDNF was measured by plotting 5 the response at equilibrium for 
varying concentrations of GDNF. Nonlinear regression analysis gave a KD of 6 ± 1 nM. 
 
to prevent mass transfer-limited kinetics.  Binding of GDNF to the glycopolymers was 
assessed by flowing GDNF over the chip at various concentrations (2, 1, 0.5 nM) and 
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recording the SPR sensorgrams (50 µL/min, 25 ºC). As shown in Figure 2.8, GDNF 
interacted with the CS-E sulfated glycopolymer, but not with the unsulfated glycopolymer, 
consistent with the microarray results.  Binding of GDNF to the CS-E sulfated 
glycopolymer was characterized by a slow initial rate of association that rapidly reached 
 
Figure 2.9. SPR sensorgram of the interaction between GDNF and a monovalent, biotinylated CS-E 
disaccharide at various GDNF concentrations (2 nm, cyan; 1 nm, magenta; 0.5 nm, black).  No 
significant binding to the monovalent CS-E disaccharide was observed. 
 
equilibrium, followed by a slow rate of dissociation.  By plotting the response at 
equilibrium for varying concentrations of GDNF (0.25–62 nM), we obtained a dissociation 
constant (KD) of 6 ± 1 nM for the interaction between GDNF and the CS-E sulfated 
glycopolymer.  It is well known that monovalent CS and heparan sulfate disaccharides 
exhibit weak binding affinity for proteins and minimal biological activity.21, 24-26  Indeed, 
binding of GDNF to a biotinylated CS-E disaccharide could not be detected under these 
conditions (Figure 2.9). Thus, the observation that our glycopolymers interact strongly with 
proteins suggests that the multivalent display of sulfated epitopes between GAG chains 
plays a critical role in enhancing their interactions with proteins.  Together, our studies 
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demonstrate that end-functionalized ROMP glycopolymers can effectively engage 
glycosaminoglycan-binding proteins and function as novel mimetics for CS 
glycosaminoglycans. 
 In order to study the effects of spacing on the binding capability of the glycopolymers,  
our group also generated norbornene polymers in which the norborne-dissacharide units are 
separated on the polymer chain by unconjugated norbornene linkers (Figure 2.10). 
 
 
Figure 2.10. CS glycopolymers with linkers to increase distance between CS disaccharide units. 
 
Microarrays were generated as described above, by spotting biotin-labeled glycopolymers 
to streptavidin-coated slides. In addition, biotinylated CS polysaccharides were also added, 
to compare the binding of the proteins to the naturally occurring CS motifs. Initial testing 
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of these arrays with the CS-E antibody revealed highly preferential binding to the CS-E 
glycopolymer and the polymer with two norbornene linkers (Figure 2.11). A much lower 
level of binding of the antibody to the CS-E polysaccharide was observed, which could be 
due to competitive effects of the CS polymers on the array surface.   
 
 
 
Figure 2.11. The CS-E antibody preferentially binds to the CS-E norbornene polymer (CS-E NB) and 
the CS-E norbornene polymer with two norbornene linkers (CS-E NB 2L). No binding was observed 
to other CS polysaccharide motifs, or to CS-A or CS-C polymers. Concentration of the 
polysaccharides/polymers is shown at right (µM). 
 
 
 
Next, we investigated the binding of several proteins on the microarray. These 
included midkine, a growth factor involved in the development in the nervous system27, 
and TNFα,  a cytokine that induces inflammation and is implicated in a variety of human 
diseases.28, 29 Both midkine and TNFα have been shown previously to bind specifically to 
CS-E.7, 14, 30 TNFα appeared to bind preferentially to the CS-E polysaccharide and the CS-E 
norbornene polymer, but not to the polymer with two linkers (Figure 2.12). Midkine bound 
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to the CS-E polysaccharide preferentially, but also seemed to bind to all of the polymers on 
the array to some degree. This may be explained by the reduced specificity of midkine to 
the CS polysaccharides, as it also appeared to bind to both CS-A and CS-C 
polysaccharides. Midkine is also known to bind to heparin and to various CS motifs31 
supporting the observation of non-specific anionic binding with this protein. GDNF was 
also tested on these arrays, and was observed to bind to the CS-E polysaccharide and to the 
CS-E norbornene polymer, but not to the polymer with two linkers.  
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Figure 2.12. Binding of proteins to CS polysaccharides, norbornene polymers (NB) and norbornene 
polymers with two norbornene linkers (CS NB 2L). Concentration of the polysaccharides/polymers is 
shown at right (µM). 
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Conclusions 
We have generated a new class of CS glycomimetic polymers that display defined sulfation 
motifs, while mimicking the multivalent architecture of native GAG chains.  Our studies 
demonstrate that these glycopolymers can be efficiently attached to surfaces, where they 
approximate physiological cell-cell and cell-extracellular matrix interactions and retain the 
ability to engage proteins.  ROMP-based glycopolymers are part of a growing arsenal of 
chemical tools for studying the structure-activity relationships of GAGs.  We anticipate that 
they will prove valuable for understanding how multivalency, not only within but also 
between, GAG chains enhances the avidity, specificity and cooperativity of GAG-protein 
interactions.  Future studies will focus on extending the methodology reported herein to 
polymers and block co-polymers with varied sulfation patterns and applying them as tools 
to manipulate CS activity in various biological contexts. The results with CS polymers 
incorporating norbornene linkers show that the spacing of the motifs on the polymer chain 
can retain the binding seen with some proteins, while the binding is lost in other proteins. 
This data, along with future experiments, can provide insight into the CS binding sites of 
proteins of interest and how different protein surfaces can interact with the CS motifs. 
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Materials and Methods 
Determination of glycopolymer concentrations. Concentrations of the glycopolymers 
were determined by measuring their relative uronic acid content using the carbazole 
reaction.32 Briefly, the acid borate reagent (1.5 ml of 0.80 g sodium tetraborate, 16.6 ml 
H2O, and 83.3 ml H2SO4) was added to 15-ml glass test tubes. The glycopolymers (5 μl of 
a 10 mg/ml stock in 3.5 M NaCl) were added and the solution placed in a boiling H2O bath 
for 10 min. Following addition of the carbazole reagent (50 μl of 0.1% w/v carbazole in 
100% EtOH), the solution was boiled for 15 min. The absorbance was read at 530 nm and 
compared to a D-glucuronolactone standard in H2O.  
Polysaccharide biotinylation. Chondroitin sulfate polysaccahrides were biotinylated as 
previousy described.33 Briefly, CS polysaccharides (2 mg; Seikagaku) were dissolved in 1 
ml of 0.05 M NaHCO3 for 30 min at room temperature. EZ-Link Sulfo-NHS-LC-LC-
Biotin (0.25 mg; Pierce) was dissolved in 1 ml of H2O, and added to each CS sample. The 
mixture was incubated at room temperature for 3 h while mixing end-over-end, and then 
dialyzed into PBS using 13,500 MW cutoff dialysis tubing. 
Biotin quantification. Incorporation of biotin into the polymers was quantified using the 
Fluorescence Biotin Quantitation Kit (Thermo Scientific). Briefly, the biotinylated 
polymers were dissolved in PBS, and DyLight Reporter (fluorescent avidin and HABA 
premix) was added to the biotinylated samples and a range of diluted biocytin standards. 
The avidin in this reporter fluoresces when the weakly interacting HABA (4´-
hydroxyazobenzene-2-carboxylic acid) is displaced by the biotin. The amount of biotin in 
the polymer samples was then determined by comparing the sample’s fluorescence to the 
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biocytin standard curve. The amount of biotin in the sample was compared to the 
predetermined polymer concentration to determine the extent of biotinylation.  
Microarray assays. Carbohydrate microarrays were generated by spotting stock solutions 
of glycopolymers in PBS (1 nl) onto streptavidin coated slides (Xenopore) using a 
Microgrid II arrayer (Biorobotics; Cambridge, UK) at room temperature and 50% 
humidity. The concentrations of the stock solutions, which ranged from 500 nM to 50 µM, 
were determined using the carbazole assay as described above and were corrected for the 
percentage of biotinylation. A given concentration of each polymer was spotted ten times at 
different positions on the array. A boundary was created around the polymer spots on the 
slides using a hydrophobic slide marker (Super Pap Pen, Research Products International), 
and the slides were blocked with 10% fetal bovine serum (FBS) in PBS (pH 7.4, unless 
otherwise indicated) with gentle rocking at 37 °C for 1 h, followed by a brief rinse with 
PBS. Human GDNF (Peprotech) was reconstituted in 1% Triton X-100 in PBS, added to 
the bound region on the slides at a concentration of 2 µM (100 µL), and incubated at room 
temperature for 3 h. The slides were briefly rinsed three times with PBS, and then 
incubated with a rabbit anti-human GDNF antibody (Peprotech; 1:1000 in 1% Triton X-
100 in PBS) for 1 h at room temperature. The slides were again rinsed with PBS, and then 
incubated with an anti-rabbit antibody conjugated to Cy3 (Jackson ImmunoResearch; 
1:5000 in PBS) for 1 h in the dark with gentle rocking. After rinsing two times with PBS 
and once with H2O, the microarray was analyzed at 532 nm using a GenePix 5000a 
scanner, and fluorescence quantification was performed using GenePix 6.0 software. 
Binding of the anti-CS-C (2D5-1D2) and anti-CS-E (2D11-2A10) antibodies7, 14 was 
evaluated as described above using 100 µL of a 10 µg/ml (or ~70nM) solution of the 
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antibody and a goat anti-mouse IgG secondary antibody conjugated to Cy3 (Jackson 
ImmunoResearch; 1:5000 in PBS).  The experiments were performed in duplicate, and data 
representing the average of 20 spots per concentration were shown.  Error bars represent 
the standard error of the mean. 
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 Chapter 3: A Sulfated Carbohydrate Epitope Inhibits 
Axon Regeneration after Injury∗
 
 
Introduction 
A major obstacle to functional recovery after CNS injury is the inhibitory 
environment encountered by regenerating axons.  Chondroitin sulfate (CS) polysaccharides 
and their associated proteoglycans (CSPGs) are the principal inhibitory components of the 
glial scar, which forms after neuronal damage and acts as a barrier to axon regeneration.1-3  
It is well established that the inhibitory activity of CSPGs is derived from their CS chains, 
as chondroitinase ABC (ChABC) treatment promotes axon regeneration, sprouting, and 
functional recovery after injury in vivo.4-7  However, the mechanisms by which CS 
polysaccharides inhibit axon growth are poorly understood.  Dissection of the structural 
determinants and mechanisms underlying CS activity is essential for understanding the 
barriers to axon regeneration and for developing new treatments to promote regeneration 
and functional recovery after spinal cord and other CNS injuries. 
 
 
                                                 
∗ This section was adapted from Brown, J. M.; Xia, J.; BinQuan, Z.; Cho, K.-S.; Rogers, C. 
J.; Gama, C. I.; Rawat, M.; Tully, S. E.; Uetani, N.; Mason, D.; Tremblay, M. L.; Peters, E. 
C.; Habuchi, O.; Chen, D. F.; Hsieh-Wilson, L. C. A Sulfated Carbohydrate Epitope 
Inhibits Axon Regeneration After Injury. Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 4768–
4773.  
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Figure 3.1. CS polysaccharides are composed of 20-200 units of the repeating disaccharide D-
glucuronic acid (GlcA) and N-acetyl-D-galactosamine (GalNAc).  The sugar hydroxyls are variably 
sulfated to give rise to diverse sulfation patterns.  Chemical structures of major sulfation motifs 
found in the mammalian nervous system: CS-A (GlcA-4SGalNAc), CS-C (GlcA-6SGalNAc) and CS-
E (GlcA-4S, 6SGalNAc).  n = 20-200. 
 
 
CS polysaccharides are composed of repeating disaccharide units, which undergo 
regiochemical sulfation during development and after injury.8-11  The CS-A (GlcA-
4SGalNAc), CS-C (GlcA-6SGalNAc) and CS-E (GlcA-4S, 6SGalNAc) disaccharides 
represent major sulfation motifs in the mammalian CNS (Figure 3.1).  Although the diverse 
sulfation patterns of CS polysaccharides lie at the heart of their biological activity, these 
complex sulfation patterns have also hampered efforts to understand the biological 
functions of CS.  For example, genetic approaches are challenged by the presence of 
multiple sulfotransferase isoforms with overlapping specificities, and deletion of a single 
sulfotransferase gene can propagate global changes throughout the carbohydrate chain.12 
The structural complexity of CS has also thwarted biochemical efforts to isolate well-
defined, sulfated molecules.  As such, only heterogeneous mixtures or purified samples 
biased toward abundant, readily isolable sequences have been available for biological 
investigations.8, 9  Although studies have suggested that the CS-A, CS-E, and CS-C motifs 
are upregulated after neuronal injury and may play roles in axon regeneration,8, 10, 13 only 
heterogeneous polysaccharides were utilized for those studies, and there has been 
conflicting data, confounding the question of whether specific sulfation sequences are 
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important.  Indeed, because of the lack of structure-activity relationships, relatively 
nonspecific mechanisms have also been proposed, such as those brought about by steric 
blockage of the extracellular space,14 arrays of negatively charged sulfate,8 or obstruction 
of substrate adhesion molecules.15 
Here, we exploited chemically synthesized CS oligosaccharides and glycopolymers 
to examine systematically the role of specific sulfation sequences in neural regeneration.  
Our studies demonstrate that the CS-E sulfation motif is a key structural determinant 
responsible for the inhibitory activity of CSPGs.  Moreover, we provide the first 
mechanistic insights into how CS-E enables CSPGs to inhibit axon growth through the 
identification of a specific neuronal receptor for CS-E.  Finally, we show that blocking the 
inhibitory CS-E sugar motif can reverse CSPG-mediated inhibition and promote axon 
regeneration in vivo, providing a novel therapeutic approach to neural regeneration. 
 
Results 
CS-E-Enriched Polysaccharides Inhibit Neurite Outgrowth and Repel Axons. To 
understand the role of specific sulfation motifs, we used CS polysaccharides enriched in 
particular motifs and exploited our ability to chemically synthesize defined CS-A, CS-C 
and CS-E oligosaccharides.  First, we compared the inhibitory effects of CSPGs and CS 
polysaccharides enriched in CS-A, CS-C or CS-E disaccharide units on neurite outgrowth.  
Neurite outgrowth of dissociated dorsal root ganglion (DRG) neurons was inhibited by 
58% of untreated control levels when grown on CSPGs (Figure 3.2A).   
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Figure 3.2. CS-E-enriched polysaccharides inhibit DRG neurite outgrowth and induce growth cone 
collapse.  (A) Dissociated chick E7 DRGs were cultured on a substratum of poly-DL-ornithine (P-
Orn control), CSPGs, chondroitinase ABC-treated CSPGs, or CS polysaccharides enriched in the 
CS-A, CS-C or CS-E sulfation motifs.  Representative images and quantitation of average neurite 
length (± SEM, error bars) from three experiments (n = 50-200 cells per experiment).  (B) 
Polysaccharides enriched in the CS-E sulfation motif, but not the CS-A or CS-C motifs, inhibit DRG 
neurite outgrowth in a dose-dependent manner.  (C) CS-E-enriched polysaccharides repel axon 
crossing in a boundary assay.  Polysaccharides (1 mg/ml) or PBS control were mixed with Texas Red 
and spotted on P-Orn coated coverslips.  Dissociated rat P5-9 CGN neurons were immunostained 
with an anti-β-tubulin antibody.  Representative images and quantitation of percentage of axon 
crossing (± SEM, error bars) from two experiments (n = 30-50 axons per experiment).  (D) CS-E-
enriched polysaccharides induce growth cone collapse.  DRG explants from chick E7-9 embryos were 
grown on a P-Orn/laminin substratum, treated with medium (control) or the indicated 
polysaccharides, and stained with rhodamine-phalloidin.  Representative images and quantitation of 
growth cone collapse (± SEM, error bars) from five experiments (n = 50-100 growth cones per 
experiment).  Arrows indicate collapsed growth cones.  All statistical analyses were performed using 
the one-way ANOVA (*P < 0.0001, relative to control).   
 
 
ChABC digestion largely abolished the effects, confirming the importance of the CS 
chains.16 CS polysaccharides enriched in the CS-E motif potently inhibited neurite 
outgrowth to ~50% of untreated control levels as suggested previously8 and in a dose-
dependent manner (Figure 3.2A and 2.2B).  In contrast, polysaccharides enriched in the 
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CS-A or CS-C motif had no appreciable inhibitory effects on neurite outgrowth at the same 
glucuronic acid concentrations.  The lack of inhibition observed for CS-A and CS-C, even 
when used at 100-fold higher concentrations than CS-E (Figure 3.2B), suggests that the 
inhibitory activity of CS-E polysaccharides is not simply due to their high overall negative 
charge.  Similar results were obtained with cerebellar granule neurons (CGNs; Figure 3.3), 
whose neurite growth is inhibited by CSPGs.16  
 
 
Figure 3.3. Polysaccharides enriched in the CS-E sulfation motif (60% CS-E content), but not CS-A 
or CS-C (90% CS-A and CS-C content, respectively), inhibit the neurite outgrowth of cerebellar 
granule neurons (CGNs). (A) Dissociated P5-9 rat CGNs were cultured on a substratum of 
polysaccharides enriched in the CS-A, CS-C or CS-E sulfation motifs (1 µg/ml) for 24 h. Cells were 
immunostained using an anti-βIII-tubulin antibody, imaged and quantified using the NIH software 
ImageJ.  Representative images are shown on the top, and quantitation of the average neurite length 
(± SEM, error bars) from at least three experiments is shown on the bottom (One-way ANOVA, *P < 
0.0001, relative to P-Orn control; n = 50–200 cells per experiment). (B) Polysaccharides enriched in 
the CS-E sulfation motif, but not the CS-A or CS-C motifs, inhibit CGN outgrowth in a dose-
dependent manner (top). Chondroitinase ABC digestion abolishes the inhibitory properties of CS-E-
enriched polysaccharides in CGNs (bottom). 
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Figure 3.4. Representative images of the (A) axon repellant activity of CS-A and CS-E 
polysaccharides at high sugar concentrations (10 mg/ml) and (B) growth cone collapse in rat P7-9 
CGN explants induced by CS-E polysaccharides. Scale bars, 30µm. 
 
 
As CSPGs in the glial scar form an inhibitory boundary to growing axons, we 
examined whether polysaccharides enriched in the CS-E sulfation motif could repel axons 
in a boundary assay. Like CSPGs,17 CS-E-enriched polysaccharides formed an inhibitory 
zone that was strongly repellent to CGN axons (Figure 3.2C).  In contrast, axons freely 
crossed into boundaries enriched in the CS-A or CS-C motifs. CS-A-enriched 
polysaccharides also exhibited repulsive behavior as reported,9 but much higher 
concentrations of sugar were required (Figure 3.4A).   
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It is known that CSPGs can acutely collapse growth cones to form dystrophic 
axonal structures that no longer extend, thus leading to long-term inhibition of regrowth.18  
To examine whether CS-E is involved in the acute phase of the inhibitory response, we 
performed growth cone collapse assays.  Application of CS-E-enriched polysaccharides to 
DRG or CGN explants significantly increased the number of collapsed growth cones within 
minutes (Figure 3.2D and Fig. 2.4B), whereas CS-A- and CS-C-enriched polysaccharides 
had no effect.  Taken together, these results indicate that CS polysaccharides are sufficient 
to recapitulate the inhibitory effects of CSPGs on neurons, and this activity depends 
critically on the CS sulfation pattern.   
 
Figure 3.5. The CS-E motif is a potent inhibitor of axon growth.  (A) Structures of synthetic 
glycopolymers displaying pure CS-A, CS-C and CS-E disaccharides.  (B) The synthetic CS-E 
glycopolymer inhibits neurite outgrowth of chick E7 DRGs, whereas the CS-A glycopolymer, CS-C 
glycopolymer, and monovalent CS-E disaccharide have little effect.  (C) The synthetic CS-E 
glycopolymer induces DRG growth cone collapse.  (D) CSPGs from CS-E-deficient mice show 
significant loss of inhibitory activity on DRG neurite outgrowth. Mouse P8 DRGs were cultured on 
CSPGs purified from Chst15 knockout or wild-type mice.  Statistical analyses were performed using 
the one-way ANOVA (*P < 0.0001, relative to control). 
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Pure CS-E Potently Inhibits Neurite Outgrowth and Collapses Growth Cones.  
Although natural polysaccharides enriched in CS-E shed light on how specific sulfation 
motifs function in CSPG-mediated axon inhibition, these data should be interpreted 
cautiously because polysaccharides containing a single, pure sulfation sequence have not 
traditionally been isolated from natural sources, and thus the possibility that the inhibitory 
activity is due to minor, contaminating motifs cannot be eliminated.  Indeed, about 40% of 
the CS-E-enriched polysaccharide contains other sulfation motifs, and rare sulfation 
sequences are likely to be biologically important, as in the case of heparan sulfate 
glycosaminoglycans.19, 20  As such, the intrinsic structural complexity and heterogeneity of 
CS pose a major obstacle to understanding structure-activity relationships.   
To overcome this problem, we synthesized homogeneously sulfated glycopolymers 
displaying only the CS-A, CS-C or CS-E sulfation motifs (Figure 3.5A).  Norbornene-
linked CS-A, CS-C or CS-E disaccharides were polymerized using ruthenium-catalyzed 
ring-opening metathesis polymerization (ROMP) chemistry. This approach generates 
glycopolymers of pure, defined sulfation sequence with molecular weights and biological 
activities comparable to natural CS polysaccharides.21 Previously, we showed that these 
molecules were powerful tools to study the roles of specific CS motifs in promoting neurite 
outgrowth of developing hippocampal neurons.22 In the context of DRG neurons, 
glycopolymers containing pure CS-E inhibited neurite outgrowth, whereas those containing 
pure CS-A or CS-C had minimal activity (Figure 3.5B and Figure 3.6).  Moreover, the 
monovalent CS-E disaccharide at the same uronic acid concentration did not inhibit neurite 
outgrowth, confirming that the multivalent presentation of CS-E is critical for biological 
activity.  Similarly, we found that glycopolymers containing pure CS-E potently induced 
52 
growth cone collapse in DRG explants (Figure 3.5C), whereas CS-A or CS-C 
glycopolymers had no effect.  As CS polysaccharides are found as a complex mixture of 
different sulfation patterns in vivo, we also examined the activity of a glycopolymer 
mixture.  A 1:1 mixture of CS-A and CS-E glycopolymers had no further effects on 
 
 
Figure 3.6. Representative images of the (A) inhibition of chick E7 DRG outgrowth by the synthetic 
glycopolymers, and (B) growth cone collapse of chick E7-9 DRG explants induced by the synthetic 
glycopolymers. Arrows indicate collapsed growth cones.  (C) Higher magnification images (60x) of 
intact and collapsed growth cones. Scale bars A and B: 100 µm; C: 20 µm. 
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neurite outgrowth compared to the pure CS-E glycopolymer alone, confirming that sulfated 
mixtures do not confer additional inhibitory properties (Figure 3.7).   
To complement our chemical approaches, we also investigated the contribution of 
the CS-E motif using genetic methods.  We isolated CSPGs from mice containing a 
targeted gene disruption of N-acetylgalactosamine 4-sulfate 6-O sulfotransferase 15 
(Chst15), the enzyme that generates CS-E via addition of a sulfate group to the 6-O 
position of GalNAc on CS-A.23  Consistent with potent inhibitory activity for CS-E, 
 
 
Figure 3.7. A mixture of the CS-A and CS-E synthetic glycopolymers does not confer additional 
inhibitory properties compared to the pure CS-E glycopolymer.  Dissociated E7 chick DRGs were 
cultured on the indicated substrates for 12-14 h.  Cells were immunostained using an anti-βIII-
tubulin antibody, imaged, and quantified using the NIH software ImageJ.  Quantitation of average 
neurite length (± SEM, error bars) from three experiments (n = 100-150 cells per experiment) is 
shown. 
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Figure 3.8. The CS-E sulfation motif inhibits axon growth via PTPσ.  (A) Inhibitors against EGFR 
(AG1478, 15 nM) and ROCK (Y27632, 5 µM) rescued CS-E- and CSPG-mediated inhibition of 
neurite outgrowth in dissociated rat P5-9 CGN cultures, whereas JNK inhibitor II (10 µM) had no 
effect.  Quantitation of neurite outgrowth from three experiments is reported.  (One-way ANOVA, 
*P < 0.0001, relative to CS-E control without inhibitors, **P < 0.0001, relative to CSPG control 
without inhibitors; n = 50-200 cells per experiment).  (B) PTPσ binds selectively to CS-E-enriched 
polysaccharides on glycosaminoglycan microarrays.  Microarrays were incubated with PTPσ-Fc, 
followed by a Cy3-conjugated anti-human IgG secondary antibody, and analyzed using a GenePix 
5000a scanner.  Graphs show quantification from three experiments (n = 10 per condition).  (C) Co-
precipitation of CS-E and PTPσ. Full-length PTPσ-mycHis was expressed in COS-7 cells and 
incubated with biotinylated CS-E or CS-C polysaccharides bound to streptavidin beads.  PTPσ 
binding was detected by immunoblotting with an anti-myc antibody.  (D) Specific, high affinity 
binding of CS-E polysaccharides to PTPσ.  (E) PTPσ-/- neurons show significantly less inhibition by 
CS-E than wild-type control neurons. For each genotype, the percentage inhibition of neurite 
outgrowth is plotted relative to neurons treated with only P-Orn.  Quantification from three 
experiments is shown. (One-way ANOVA, *P < 0.005, relative to control; n = >200 cells per 
experiment). 
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removal of CS-E from CSPGs resulted in significant loss of inhibitory activity on DRG 
neurite outgrowth (Figure 3.5D).  The remaining inhibitory effect of CSPGs from Chst15-/- 
mice is likely due to the proteoglycan core protein or other proteins in the mixture, as 
treatment with ChABC to remove CS chains did not reduce the inhibitory effects any 
further.  Taken together, our chemical and genetic studies demonstrate conclusively that the 
CS-E motif is a potent inhibitor of axon growth and a critical inhibitory structure on 
CSPGs. 
The CS-E Motif Activates Inhibitory Signaling Pathways.  To investigate the molecular 
mechanisms by which CS-E inhibits axon growth, we examined the ability of CS-E to 
activate signaling pathways associated with inhibition of axon regeneration.  CSPGs and 
myelin inhibitors have been shown to activate Rho/Rho-kinase (ROCK) and epidermal  
 
Figure 3.9. Inhibitors to EGFR, ROCK, and JNK alone have no effect on CGN outgrowth in the 
absence of CS-E or CSPGs.  Dissociated rat P5-9 CGN neurons were cultured on a P-Orn 
substratum in the presence or absence of inhibitors against EGFR (AG1478, 15 nM), ROCK 
(Y27632, 5 µM), and JNK (inhibitor II, 10 µM) for 24 h. Neurites were visualized by staining with an 
anti-β-tubulin III antibody, and quantitation of neurite outgrowth from at least three independent 
experiments is shown (n = 50–200 cells per experiment).   
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growth factor receptor (EGFR) pathways.9, 16, 17, 24  Pharmacological inhibition of these 
signaling pathways effectively reversed the inhibitory effects of CSPGs on CGN neurons 
(Figure 3.8A and Figure 3.9).  Specifically, the EGFR competitive inhibitor AG1478and 
the ROCK inhibitor Y27632 restored neurite outgrowth to within 79-88% of untreated 
control levels, in agreement with previous studies.16, 17, 24  Importantly, we found that the 
EGFR and ROCK inhibitors also neutralized the inhibitory activity of CS-E 
polysaccharides and rescued neurite outgrowth to a similar extent.  In contrast, inhibition of 
c-Jun N-terminal kinase (JNK) pathways using JNK inhibitor II showed no effect on either 
CS-E- or CSPG-mediated neurite inhibition, as expected.17  Moreover, treatment of COS-7 
cells with CS-E or CSPGs led to activation of RhoA (Figure 3.10).   
 
 
Figure 3.10. CS-E and CSPGs activate RhoA.  Serum starved COS-7 cells treated with CS-E 
polysaccharides or CSPGs (10 µg/ml) for 10 min. Cell lysates were standardized for total protein 
concentration and then added to a 96-well plate containing immobilized rhotekin-RBD, which binds 
the active (GTP-bound) form of RhoA.  Bound RhoA was detected using a RhoA antibody followed 
by a horseradish peroxidase-labeled secondary antibody. Relative luminescence units (RLU) are 
plotted relative to that of the untreated control (cell medium alone) for two experiments.   
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Thus, CS-E activates intracellular signaling pathways involved in CSPG-mediated 
inhibition of axon regeneration, further supporting the notion that this sugar epitope is a 
major inhibitory component of CSPGs.   
The CS-E Motif Inhibits Neurite Outgrowth via PTPσ.  The ability of CS-E to trigger 
downstream signaling pathways suggests that CS-E may directly engage protein receptors  
 
 
Figure 3.11. PTPσ-Fc but not Fc alone or EphA2-Fc bind preferentially to CS-E-enriched 
polysaccharides.  Representative portion of the microarray after binding to PTPσ-Fc (A, left) or Fc 
control (B, left).  Quantitation from three experiments is shown on the right.  Each bar (A and B, 
right) represents an average of 10 spots per carbohydrate concentration. (C) EphA2-Fc binding to 
carbohydrate microarrays. Binding relative to PTPσ-Fc is shown. 
 
58 
at the cell surface, thereby initiating intracellular signaling.  Recently, CSPGs were shown 
to interact with protein tyrosine phosphatase PTPσ, a transmembrane receptor known to 
bind heparan sulfate proteoglycans.6, 25  PTPσ gene disruption reduced axon inhibition by 
CSPGs in culture6 and enhanced regeneration in sciatic, facial, optic, and spinal cord nerves 
in vivo.6, 26-28  However, it remains unknown whether (and which) specific sulfation motifs 
on CS mediate the interactions of CSPGs with PTPσ. 
In light of our results showing that CS-E is a major inhibitory motif on CSPGs, we 
examined the potential interaction between CS-E and PTPσ using carbohydrate 
microarrays.29  A soluble PTPσ-Fc fusion protein, but not other receptors such as EphA2-
Fc or Fc alone, bound efficiently to CS-E polysaccharides arrayed on poly-lysine-coated 
glass slides (Figure 3.8B and Figure 3.11).  PTPσ showed strong binding to heparin and 
CS-E polysaccharides, with weaker binding to chondroitin sulfate and dermatan sulfate 
(both of which contain some CS-E) and heparan sulfate.  Little or no binding to CS-A, CS-
C, or CS-D polysaccharides was observed, highlighting the specificity of PTPσ for the CS-
E sulfation motif.   
To confirm further the PTPσ-CS-E interaction, biotinylated CS-E or CS-C 
polysaccharides were conjugated to streptavidin beads and incubated with COS-7 cell 
lysates expressing full-length PTPσ.  We found that CS-E polysaccharides were capable of 
pulling down PTPσ, whereas CS-C polysaccharides showed no interaction (Figure 3.8C).  
In addition to this heterologous cell system, we captured PTPσ from a rat brain membrane 
protein-enriched fraction and identified the protein by mass spectrometry analysis (Figure 
3.12).  Lastly, we showed that biotinylated CS-E, but not CS-A or CS-C, polysaccharides 
bind immobilized PTPσ with high affinity according to a Langmuir binding model (Figure 
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3.8D). The apparent dissociation constant (KD, app) of approximately 1 nM is similar to 
values reported for the association of PTPσ with the CSPGs neurocan and aggrecan.6   
Having demonstrated that CS-E interacts specifically with PTPσ, we next tested 
whether CS-E and PTPσ form a functional association.  Deletion of PTPσ significantly 
attenuated CS-E-induced inhibition of neurite outgrowth in DRG neurons (Figure 3.8E), 
indicating that PTPσ is required for CS-E to inhibit neurite outgrowth.  Interestingly, 
residual inhibition by CS-E (~22%) remained in PTPσ-deficient neurons, consistent with 
previous observations with CSPGs.6  These results suggest that CS-E may also engage 
other receptors, possibly leukocyte common antigen-related phosphatase (LAR)30 and as-
yet-undiscovered receptors, although we cannot rule out additional receptor-independent 
mechanisms, such as charge repulsion or reduced cell adhesion.  Together, these studies 
demonstrate that the fine structure of CS chains mediates interactions with receptors 
involved in axon regeneration, and they identify PTPσ as a critical functional receptor for 
CS-E. 
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Figure 3.12. PTPσ peptides identified by LC-MS/MS analysis. PTPσ from rat brain lysates was 
pulled down using CS-E and resolved by SDS-PAGE. In-gel tryptic digestion and LC-MS/MS 
analysis revealed two unique peptides within PTPσ. The annotated spectra from collision-activated 
dissociation mass spectrometry (CAD-MS) of the peptides show the y and b fragment ions enabling 
identification. 
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Figure 3.13. A monoclonal antibody binds specifically to CS-E and blocks CSPG-mediated neurite 
inhibition. (A) Binding of the CS-E antibody to carbohydrate microarrays.  Little binding to other 
sulfated CS polysaccharides or glycosaminoglycan classes was detected. Experiments were 
performed in triplicate (n =10 per condition).  (B) Dose-dependent binding of the anti-CS-E antibody 
to CSPGs, as shown by an enzyme-linked immunosorbent assay.  The experiment was performed in 
triplicate, and average values (± SD, error bars) are shown for one representative experiment.  (C) 
The CS-E antibody blocks CSPG-mediated inhibition of neurite outgrowth.  Dissociated chick E7 
DRGs were cultured on a substratum of P-Orn (control) or CSPGs (0.5 µg/ml) in the presence of the 
indicated antibodies (0.1 mg/ml) for 12 h.  Quantitation from three experiments is shown (One-way 
ANOVA, *P < 0.0001, relative to CSPG without antibody treatment control; n = 50–200 cells per 
experiment).   
 
 
 
62 
Generation of a Selective CS-E Blocking Antibody.  An important implication of these 
results is that blocking CS-E interactions may prevent the inhibition caused by CSPGs and 
promote axon regeneration.  To generate a CS-E blocking agent, we raised a monoclonal 
antibody against a pure synthetic CS-E tetrasaccharide.31  Although antibodies have been 
generated previously using CS polysaccharides as antigens,32, 33  their specificity has been 
limited by the structural heterogeneity of natural polysaccharides.  Synthetic chemistry has 
the advantage of providing defined molecules of precise sulfation sequence, which can be 
used as antigens, for screening antibodies, and for characterizing binding specificities.  An 
antibody generated in this manner was highly selective for the CS-E sulfation motif, as 
measured by dot blot, ELISA, carbohydrate microarrays, and surface plasmon resonance 
(Figure 3.13A, Figure 3.14, and Figure 3.15).  Strong binding to pure CS-E tetrasaccharides 
and natural CS-E polysaccharides was observed, with minimal binding to CS-A or CS-C 
tetrasaccharides and other glycosaminoglycan classes.  Notably, this antibody also bound a 
mixture of CSPGs derived from chick brain (Figure 3.13B), confirming the presence of the 
CS-E epitope on CSPGs, and blocked the interaction of CS-E polysaccharides with PTPσ 
(Figure 3.16).  
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Figure 3.14. The anti-CS-E antibody selectively binds to a pure CS-E tetrasaccharide and natural 
CS-E-enriched polysaccharides, whereas it does not bind to CS-A or CS-C tetrasaccharides or 
natural polysaccharides.  (A) Tetrasaccharides containing pure CS-A, CS-C or CS-E motifs were 
conjugated to bovine serum albumin (BSA) and spotted on nitrocellulose membranes at the indicated 
amounts.  Binding of the antibody to the membrane was detected using an Alexa Fluor 680-
conjugated goat anti-mouse secondary antibody. The anti-CS-E antibody bound in a concentration-
dependent manner to the BSA-CS-E tetrasaccharide conjugate but did not bind significantly to BSA-
CS-A, BSA-CS-C, or BSA alone. (B) Binding of the anti-CS-E antibody to biotinylated CS 
polysaccharides enriched in the CS-A, CS-C, or CS-E sulfation motifs. Biotinylated CS 
polysaccharides were absorbed on streptavidin-coated plates, and antibody binding to the plate was 
detected using a goat anti-mouse secondary antibody conjugated to horseradish peroxidase.  
Experiments were repeated in triplicate. 
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Figure 3.15. Kinetic analysis of the interaction between the anti-CS-E antibody and CS-E 
tetrasaccharide by surface plasmon resonance. (A) The synthetic CS-E tetrasaccharide was 
covalently immobilized onto the surface via reductive amination chemistry. Kinetics were monitored 
at 25 ºC by injecting the CS-E antibody over the surface for 300 s at 30 µl/min and recording the 
disassociation for 900 s before the surface was regenerated with 6 M guanidine HCl. The resulting 
sensorgrams were fit to the bivalent analyte model. According to this model, a surface-bound analyte 
can bind another ligand molecule with the free binding site. The kinetic parameters of the fit, with 
standard errors in parentheses, are tabulated in (C). The affinity was also measured by injecting the 
antibody over the surface for 3600 s to give sufficient time to reach equilibrium. The response at 
equilibrium was plotted versus concentration to give a KD of 4.3 nM (B). 
 
 
 
Figure 3.16. The CS-E monoclonal antibody (mAb) attenuates binding of CS-E polysaccharides to 
PTPσ-Fc.  PTPσ-Fc was immobilized in protein A-coated 96-well plates.  Biotinylated CS-E (10 nM) 
in PBS was added in the presence of PBS (control), CS-C mAb (10 µM), or CS-E mAb (10 µM).  
Binding of CS-E was detected using a streptavidin-horseradish peroxidase conjugate. The 
experiment was performed in duplicate.   
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Figure 3.17. CS-E neutralizing antibodies promote optic nerve regeneration. (A) a-c: 
Immunofluorescence labeling of CS-E expression in optic nerve sections at day 1 sham-operation (a), 
optic nerve crush injury (b) or optic nerve crush injury plus ChABC treatment. Note upregulation of 
CS-E around the injury site (b) that was removed by ChABC treatment (c). d-g: Representative 
epifluorescence photomicrographs of optic nerve sections taken from mice treated with control IgG 
(d), CS-E antibody (e), ChABC (f) or ChABC plus CS-E antibody (g). Asterisk indicates the crush 
site. Retinal ganglion cell axons (red) are labeled by an anterograde axon tracer, CTB, which was 
injected into the vitreous 3 days prior to scarify, followed by immunostaining with goat-anti-CTB 
antibody. In control antibody-treated mice (d), few regenerating axons are evident. In contrast, 
numerous regenerating axons were seen extending pass the crush site in CS-E antibody, ChABC or 
the combine-treated groups (e-g). Scale bars: 75 µm (a-g); 25 µm (d’-f’). Arrowheads indicate growth 
cone structures. (g) Quantification of the numbers of regenerating axons at different distances from 
the injury site.  (B) Quantification of axon regeneration in vivo.  Nerve fibers were counted at 125-
µm intervals from the crush site from three non-consecutive sections, and the number of fibers at a 
given distance was calculated (± SEM, error bars).  Both the anti-CS-E- and ChABC-treated groups 
showed significantly more regenerating axons as compared with the control IgG antibody-treated 
group (ANOVA with Bonferroni posttests at each distance, *P < 0.001 as compared to controls; n = 6 
for each group).  (C) Quantification of the distances of axon regeneration. Longest distance of axon 
regeneration was measured from at least four non-consecutive optic nerve sections from each mouse 
(± SEM, error bars).  Combined treatment of CS-E mAb and CPT-cAMP more than doubled the 
distance of axon regeneration but did not affect the number of regenerating axons compared to the 
anti-CS-E or CPT-cAMP treatment alone (Fig. 3.18). 
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CS-E Blocking Antibody Promotes Axon Regeneration.  To test whether blocking the 
CS-E epitope reverses the inhibitory effects of CSPGs, we added the CS-E antibody to 
DRG neurons grown on a substratum of CSPGs.  Neurite inhibition by CSPGs was 
significantly decreased by addition of the CS-E antibody, with neurite outgrowth returning 
to 79% of control levels (Figure 3.13C).  In contrast, neither a CS-A monoclonal antibody 
nor an IgG control antibody had any effect on CSPG-mediated neurite outgrowth.   
Having demonstrated specific blocking of CSPG activity in vitro, we next 
examined whether the CS-E antibody could promote axon regeneration in vivo.  We 
performed an optic nerve crush injury in mice,34 which causes focal damage and glial 
scarring in the optic nerve35 and thus presents an ideal model for evaluating the effects of 
local application of the CS-E antibody on axon regeneration.  Supporting the notion that 
CS-E is a prominent inhibitory component associated with CSPGs, pronounced 
upregulation of CS-E was rapidly observed around the lesion site within 1 day after the 
injury (Figure 3.17A).  To examine the effects of the CS-E antibody on axon regeneration, 
gelfoam soaked in a solution containing the CS-E or control IgG antibody was placed 
around the crush site of the nerve immediately after the injury and replaced twice at day 
three and six.  The extent of axonal regrowth was assessed 2 weeks after injury by 
anterograde axon tracing with choleratoxin-B subunit (CTB), which was injected 
intravitreally 3 days before mice were sacrificed.  Little axon regeneration was observed in 
the control antibody-treated group.  In contrast, the CS-E antibody treatment resulted in 
substantial axonal regrowth, with a six-fold increase in the number of regenerating axons 
when counted at 0.25 mm beyond the injury site, as compared with control antibody-treated 
mice (Figure 3.17B).  Notably, the extent of axon regeneration observed after CS-E 
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antibody treatment was comparable to that seen in mice treated with ChABC alone (50 
U/ml) or with ChABC and CS-E antibody applied simultaneously (50 U/ml and 1.7 mg/ml, 
respectively).  Thus, blockade of CS-E activity induced a similar extent of axon 
regeneration as complete removal of CS chains from the CSPGs, underscoring the 
inhibitory potency of CS-E in vivo.  To rule out the possibility that the observed axon 
regrowth after CS-E antibody treatment was simply due to improved cell survival, we 
stained retinal sections with an anti-β-tubulin antibody to image retinal ganglion cells and 
counted the number of surviving cells.  No detectable increase in retinal ganglion cell  
 
Figure 3.18. The CS-E antibody does not affect the survival or intrinsic growth status of retinal 
ganglion cells. (A) Application of the CS-E antibody does not change retinal ganglion cell survival 
after optic nerve injury.  Bar graph indicates relative survival of retinal ganglion cells in control IgG 
or CS-E antibody treated mice that were quantified at 14 days post-optic nerve injury.  (B) 
Comparison of axon regeneration in vivo induced by the CS-E antibody and/or CPT-cAMP.  Retinal 
ganglion cell axons were counted at 125-µm intervals from the crush site from three nonconsecutive 
sections, and the number of fibers at a given distance was calculated as previously described (5) (± 
SEM, error bars). (ANOVA with Bonferroni posttests at each distance, *P < 0.001 as compared to 
controls; n=6 for each group.      
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survival was found in the CS-E antibody-treated mice, as compared with control antibody-
treated mice (Figure 3.18).  Remarkably, these results indicate that the complex process of 
CSPG-mediated neuronal inhibition can be broken down into discrete, active components, 
which when blocked are sufficient to promote axonal regeneration in vivo. 
Combining the CS-E Blocking Antibody with Other Treatments.  The failure of axons 
to regenerate has been attributed to inhibitory molecules in the extrinsic environment and a 
reduced intrinsic regenerative capacity of mature CNS neurons.1, 2, 36, 37  We therefore 
examined the ability of the CS-E antibody to enhance axon regrowth in vivo when used in 
combination with 8-(4-chlorophenylthio)-cyclic AMP (CPT-cAMP), a cAMP analog 
known to penetrate the cell membrane and activate the intrinsic growth state of neurons.38  
In agreement with stimulation of the growth potential of retinal ganglion cell axons, 
treatment of CPT-cAMP increased the number of regenerating axons by 12-fold compared 
to the control treated group (Figure 3.18).  Combined delivery of the CS-E antibody and 
CPT-cAMP stimulated longer axonal regrowth than either drug treatment alone, increasing 
the distance of regeneration by more than 3-fold (Figure 3.17C).  The number of 
regenerating axons compared to the CPT-cAMP treatment alone was not affected (Figure 
3.18), further supporting the notion that CS-E contributes to the environmental inhibition, 
but not the intrinsic growth status, of retinal ganglion cell axons.  These results demonstrate 
the potential of combining the CS-E antibody to block inhibitory CSPGs in the 
extracellular matrix with growth-promoting treatments to enhance the regenerative 
outcome.   
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Conclusions 
It has long been recognized that CSPGs are one of the major inhibitors of neural 
regeneration, but until recently, the structural determinants and mechanisms underlying 
their activity have been poorly understood.  In particular, the precise role of the CS sugars 
and the importance of specific sulfation motifs have been unclear, limiting the development 
of molecular approaches to counteract CSPGs.  Our studies identify a sugar epitope on 
CSPGs that is primarily responsible for the inhibitory effects of CSPGs.  We show for the 
first time that the CS-E motif interacts directly with the PTPσ receptor and activates 
signaling pathways involved in inhibiting axon growth. These findings defy the 
conventional view that CSPGs function primarily as a mechanical barrier to axon 
regrowth14 and that chondroitin sulfate sugars play non-specific, passive roles.  The ability 
to upregulate particular sulfated epitopes on the sugar side chains may be essential for 
regulating CSPG activity by allowing for more precise control beyond mere expression of 
the core protein.  Further, the concerted expression of diverse sulfated epitopes on different 
CSPGs could provide an elegant mechanism to coordinate the activities of various 
proteoglycan core proteins. 
These studies also provide a new potential strategy for promoting axon regeneration 
and neural plasticity after injury.  We show that CS-E blocking strategies can increase axon 
regeneration in vivo and can be combined effectively with other treatments, such as 
stimulation of neuronal growth, to further improve the regenerative outcome.  Previous 
studies have demonstrated that antibodies delivered to the spinal cord can improve function 
after spinal cord injury,39, 40 and new techniques may even allow antibodies into the brain 
for the treatment of neurodegenerative diseases.41, 42  Additionally, the development of 
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small-molecule antagonists of CS-E function should also be feasible by inhibiting the 
sulfotransferases responsible for CS-E biosynthesis.43, 44 Targeting specific CS sugar 
epitopes using antibodies, small molecules, or other approaches may offer fewer 
undesirable side effects and a more stable, selective, and less immunogenic alternative to 
chondroitinase ABC, which is currently being evaluated as a therapeutic treatment for 
spinal cord injury.  Given that CS-E appears to interact with multiple protein receptors and 
activate multiple signaling pathways, strategies that block the sulfated CS-E epitope may 
also prove more effective at neutralizing CSPGs than targeting individual CSPG receptors 
or pathways.  
More broadly, our results demonstrate the importance of the fine structure of CS 
chains in modulating the activity of CSPGs in vivo.  In contrast to heparan sulfate, where a 
handful of important sequences have been identified,19, 20 much less is known about the 
roles of CS sulfation.  We provide the first in vivo evidence that a specific CS-E sulfation 
motif within CS polysaccharides signals through protein receptors so as to direct important 
physiological responses.  Our studies underscore the power of synthetic chemistry to 
deliver sulfated sequences with precise spacing and orientation to assess an 
underappreciated component of the mechanism. Given the importance of 
glycosaminoglycans in processes ranging from development to viral invasion and spinal 
cord injury, an expanded view of these sulfated sugars may provide new insights into many 
critical biological processes. 
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Materials and Methods 
Neurite outgrowth assays.  Glass coverslips were coated with poly-DL-ornithine (P-Orn) 
in pH 8.5 borate buffer (0.5 mg/ml) for 2 h at 37 °C and 5% CO2, followed by CS-A, -C, -E 
polysaccharides (Seikagaku), CSPGs derived from chick brains (Millipore), digested 
CSPGs treated with ChABC (Seikagaku; 4 mU ChABC per µg CSPG), or synthesized 
polymers21 (polysaccharides and polymers at 1 µg/ml based on uronic acid content45 in 
PBS) for 2 h at 37 °C and 5% CO2.  For mixed polymer assays, the polymers were mixed at 
the given concentrations immediately prior to coating.  DRGs were dissected from day 7 
chick embryos, incubated in 0.125% trypsin w/ EDTA (Invitrogen) for 15 min at 37 °C, 
triturated to dissociate to single cell suspensions, and grown on the coverslips coated with 
the above-mentioned substrata.  Cells were grown in a growth medium composed of 
DMEM/F12, 10% horse serum, 50 ng/ml NGF (Sigma-Aldrich), and Insulin-Transferrin-
Selenium-X supplement (Invitrogen) for 12 h. For CGNs, cerebella were dissected from 
P5-9 Sprague Dawley rats, incubated in 0.125% trypsin w/ EDTA for 15 min at 37 °C, 
triturated to dissociate to single cell suspensions, and purified on discontinuous 35%-60% 
Percoll gradient.  For the signaling pathway inhibitor studies, inhibitors against EGFR 
(AG1478, 15 nM; Calbiochem), ROCK (Y27632, 5 µM; Calbiochem) and JNK (JNK 
Inhibitor II, 10 µM; Calbiochem) were added in solution at the start of culturing, and 
neurons were grown for 24 h in in DMEM/F12, 1% FBS, and N1 supplement at 37 °C and 
5% CO2.  For the antibody blocking studies, anti-CS-E, anti-CS-A,31 or IgG control 
antibodies (0.1 mg/ml) were added at the start of culturing to chick E7 DRGs, which were 
cultured as described above on glass slides with a substratum of P-Orn or CSPGs (0.5 
µg/ml) for 12 h.   
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For inhibition studies using CSPGs derived from Chst15-/- mice,23 96-well Poly-D-
Lysine Cellware plates (BD BioCoat™) were coated with CSPGs in phosphate buffered 
saline (PBS; 1 mM KH2PO4, 155 mM NaCl, 3 mM Na2HPO4, pH 7.4) overnight at 37 °C 
and 10% CO2.  The plates were then washed with PBS and coated with laminin 
(Invitrogen; 10 µg/ml) in Neurobasal medium (Invitrogen) for 2 h at 37 °C and 10% CO2.  
DRGs were dissected from P8 wild-type (WT) mouse pups, incubated in 0.125% trypsin w/ 
EDTA for 15 min at 37 °C, followed by collagenase (Worthington; 4 mg/ml) for 15 min at 
37 °C, triturated to dissociate to single cell suspensions, filtered using a 40-µm cell strainer 
(Fisher) to remove non-dissociated cells, and seeded at approximately 2000 cells per well.  
Cells were cultured for 2 days in Neurobasal medium supplemented with B27 and 
GlutaMAX™ (Invitrogen). 
 For inhibition studies using neurons from PTPσ-/- mice,46 Poly-D-Lysine Cellware plates  
were coated with laminin (10 µg/ml) in Neurobasal medium (Invitrogen) for 2 h at 37 °C 
and 10% CO2.  DRGs were dissected from adult knockout (KO) mice or WT controls, 
dissociated, and cultured as described above.  CS-E was biotinylated as described8 and 
conjugated to streptavidin agarose beads (200 µg of CS in 400 µl PBS incubated with 100 
µl agarose resin for 1 h at room temperature), which were then co-plated with the cells (5 
µg of 50% slurry per well).  Unconjugated beads at the same concentration were used as a 
control.  Cells were grown in Neurobasal medium supplemented with B27 and 
GlutaMAX™ (Invitrogen) for 2 days.  For all neurite outgrowth experiments, we 
performed statistical analysis using the one-way ANOVA; n = 50-200 cells per experiment, 
and results from at least three independent experiments were reported. 
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Growth cone collapse assays.  DRG explants were dissected from E7-9 chick embryos 
and grown in DMEM/F12 medium supplemented with horse serum (10%), Insulin-
Transferrin-Selenium-G supplement, and NGF (50 ng/ml) on 8-well Lab-Tek® II CC2™ 
slides (Electron Microscopy Sciences) that were coated with P-Orn in pH 8.5 borate buffer, 
followed by laminin (10 µg/ml) in PBS for 2 h at 37 °C and 5% CO2.  CGN explants were 
dissected from P7-9 rats, chopped with a razor blade into approximately 1-mm2 pieces, and 
cultured on P-Orn-coated glass coverslips in DMEM/F12 medium supplemented with 
horse serum (10%), FBS (5%), and N1 supplement.  After 24 h, explants were treated with 
the indicated polysaccharides or glycopolymers (10 µg/ml based on uronic acid content in 
media; initial stock: 200 µg/ml in PBS) for 30 min.  P-values were determined using one-
way ANOVA; n = 50-100 growth cones per experiment, and results from at least five 
independent experiments were reported. 
 
Boundary assays.  CS polysaccharides (1 mg/ml based on uronic acid content) were mixed 
with Texas Red (0.5 mg/ml; Invitrogen) in PBS, spotted at the center of P-Orn-coated 
coverslips (5 µl), and incubated for 2 h at 37 °C and 5% CO2.  Cerebella were dissected 
from P5-9 Sprague Dawley rats, incubated in 0.125% trypsin w/ EDTA for 15 min at 37 
°C, triturated to dissociate to single cell suspensions, and purified on a discontinuous 35%-
60% Percoll gradient. These cells were then cultured on the coated coverslips for 48 h. 
After immunostaining for neurite outgrowth, axons growing toward the boundary and 
within 10 µm distance of the boundary were evaluated.  The percentage of axons that 
crossed the boundary over the total axons was quantified.  P-values were determined using 
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one-way ANOVA; n = 30-50 axons per experiment, and results from two independent 
experiments were reported.  
 
Immunostaining and quantification. Neural cultures were fixed with paraformaldehyde, 
permeabilized with 0.1% Triton X-100 in PBS, blocked with 1% BSA in PBS, and 
incubated with a mouse anti-βIII tubulin antibody (Sigma) overnight at 4 °C, followed by 
an Alexa Fluor 488-conjugated goat anti-mouse IgG secondary antibody (Invitrogen) for 1-
2 h at room temperature for neurite outgrowth and boundary assays, or by rhodamine 
phalloidin (Pierce) for 1 h at room temperature for growth cone collapse assays.  Cells were 
imaged using a Nikon TE2000-S fluorescent microscope or Zeiss LSM Pascal, and neurite 
outgrowth was quantified using NIH software ImageJ or MetaMorph software.  Statistical 
analysis was performed using the one-way ANOVA; n = 50-500 cells per experiment, and 
results from at least three independent experiments were reported. 
 
Protein expression and binding assays.  For pull-down assays, full-length mouse PTPσ 
(Open Biosystems) was ligated into a pcDNA vector (Invitrogen) modified to fuse a myc-
His tag to the 5’ end of the insert.  COS-7 cells were transfected using Lipofectamine 
(Invitrogen) and lysed two days after transfection with 1% Triton X-100 in PBS containing 
a protease inhibitor cocktail (Roche).  Lysates were then incubated with streptavidin 
agarose resin (Pierce; 30 µl) with end-over-end mixing for 1 h at 4 °C to reduce nonspecific 
binding.  The supernatant was collected, added to 30 µl of either CS-C or CS-E streptavidin 
agarose resin, and incubated with end-over-end mixing for 4 h at 4 °C.  The supernatant 
was removed, and the resin was washed three times with PBS (500 µl).  Resin was boiled 
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with 2X loading dye (30 µl of 100 mM Tris, 200 mM DTT, 4% SDS, 0.10% bromophenol 
blue, 20% glycerol), and the eluate was resolved by SDS-PAGE and transferred to PVDF 
membrane.  PTPσ-myc was detected by immunoblotting with an anti-myc antibody (Cell 
Signaling) following the manufacturer’s protocol.  For ELISA and microarray assays, the 
extracellular domain of PTPσ was ligated into a pcDNA vector that had been modified to 
append a human Fc domain and myc-His tag to the expressed protein.  HEK293T cells 
were transfected using Lipofectamine, and the conditioned media was collected and used 
for ELISA or subjected to Ni-NTA agarose purification for carbohydrate microarray 
assays.  
 
ELISA and dot blot assays.  To assay for PTPσ binding, PTPσ-Fc was incubated in 96-
well protein A-coated plates (Pierce) overnight at 4 °C.  The plates were washed with PBS 
containing 0.05% Tween-20 (PBST) and then incubated with biotinylated CS-A, CS-C, or 
CS-E polysaccharides in PBS for 2 h at room temperature.  For the antibody blocking 
study, biotinylated CS-E (10 nM in PBS) was preincubated with the CS-C antibody47 or 
CS-E antibody (10 µM) for 1 h at room temperature.  The plates were then blocked with 
1% BSA in PBS for 30 min at room temperature, incubated with horseradish peroxidase-
conjugated streptavidin (Pierce; 1:25,000) for 1 h, and developed with TMB substrate 
(3,3´,5,5´-tetramethylbenzidine; Pierce) for 20 min and quenched with 2M H2SO4.  The 
absorption at 450 nm was recorded on a PerkinElmer Victor plate reader.  Experiments 
were performed in triplicate, and data represent the mean ± SEM, error bars.  
For CS-E antibody binding to CSPGs, CSPGs (10 µg/ml; 25 µl) were incubated in 
a Nunc Maxisorp 384-well plate for 2 h.  After blocking with 3% BSA in PBS, the anti-CS-
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E antibody (at the indicated concentrations in 1% BSA in PBS) was incubated in each well 
for 2 h.  For CS binding assays, streptavidin (20 µg/ml; 50 µl) was absorbed in each well 
for 1 hr, followed with biotinylated CS (20 µg/ml; 50 µl) for 1 hr. After blocking with 3% 
BSA in PBS, the anti-CS-E antibody (25 µl of 20 µg/ml or indicated concentrations in 1% 
BSA in PBS) was incubated in each well for 2 hr. Following incubation with horseradish 
peroxidase-conjugated anti-mouse IgG secondary antibody, the plates were developed and 
analyzed as described above. Dot blot assays for binding of CS-E Ab to CS 
polysaccharides were performed as described previously.31 
 
Microarray assays. Microarrays were generated as described previously.29 Arrays were 
blocked with 10% FBS in PBS with gentle rocking at 37 °C for 1 h, followed by a brief 
rinse with PBS. PTPσ-Fc, EphA2-Fc (R & D Systems), or Fc was reconstituted in 1% BSA 
in PBS, added to the slides in 100 µl quantities at a concentration of 1 µM, and incubated at 
room temperature for 3 h.  The slides were briefly rinsed three times with PBS, and then 
incubated with a goat anti-human IgG antibody conjugated to Cy3 (Jackson 
ImmunoResearch; 1:5,000 in PBS) for 1 h in the dark with gentle rocking, and scanned at 
532 nm using a GenePix 5000a scanner.  Fluorescence quantification was performed using 
GenePix 6.0 software (Molecular Devices).  Binding of the CS-E antibody was evaluated 
using 100 µl of a 1 µg/ml (or ~7 nM) solution of antibody and a goat anti-mouse IgG 
secondary antibody conjugated to Cy3.  Experiments were performed in triplicate, and the 
data represent the average of 10 spots per concentration averaged from the three 
experiments (± SEM, error bars). 
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Mass spectrometry analysis. Brains were dissected from P7-P9 Sprague Dawley rats, 
homogenized in 0.32 M sucrose with protease inhibitors (Roche), and centrifuged at 1,000 
g for 10 min.  The supernatant was collected, and then centrifuged at 10,000 g for 20 min.  
The pellet was discarded, and the supernatant was centrifuged again at 12,000 g for 30 min.  
This supernatant was then ultra-centrifuged at 200,000 g for 1 h, and the pellet was saved 
and homogenized again in 0.32 M sucrose with protease inhibitors.  The supernatant was 
again ultra-centrifuged at 200,000 g for 1 h and the pellet was saved, solubilized in 1% 
Triton X-100 (PBST) with protease inhibitors, and centrifuged at 12,000 g for 15 min.  The 
final supernatant was obtained as the membrane protein-enriched fraction and incubated 
with CS-E or unsulfated CS conjugated to streptavidin agarose resin (described above) 
overnight at 4 ºC.  The resin was washed with PBS, and the PBS was collected and 
measured until the OD280 was less than 0.05.  The bound proteins were then eluted with 
PBS containing 500 mM NaCl.  The eluted proteins were then dialyzed into PBS and 
subjected to SDS-PAGE.  The resulting gel was stained with Coomassie Brilliant Blue, and 
the band at 206 kDa was cut out, subjected to tryptic digestion, and analyzed by liquid 
chromatography–mass spectrometry (LC-MS) analysis as reported.48  
 
Surface plasmon resonance.  All experiments were performed on a Biacore T100 at 25 ºC 
using a Sensor Chip CM5 with a running buffer composed of 0.01 M HEPES, pH 7.4, 0.15 
M NaCl, 3 mM EDTA, 0.05% Surfactant P20 (HBS-EP+).  To analyze the binding of the 
CS-E antibody to the CS-E tetrasaccharide, both control and active flow cells were exposed 
to a 1:1 mixture of N-hydroxysuccinimide (NHS) and 1-ethyl-3,3-dimethylaminopropyl-
carbodiimide (EDC) for 3 min at a flow rate of 10 μl/min.  Next, 5 mM carbohydrazine was 
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injected at the same flow rate for 7 min.  Ligand was covalently attached to the surface by 
injecting a 0.5 mM solution of synthetic CS-E tetrasaccharide bearing an aldehyde group 
on a reducing-end linker, prepared as previously described,47 onto the active flow cell 
briefly at a high flow rate (10 s, 60 μl/min), followed by a 20 min injection of 0.1 M 
sodium cyanoborohydride in 0.1 M sodium acetate pH 4.0 at 2 μl/min.  Because of the low 
molecular weight of the CS-E tetrasaccharide, it was not possible to observe the amount of 
ligand bound to the surface.  Instead, 500 nM of the CS-E antibody was injected into both 
the control and active flow cell to test the response.  The amount of ligand was increased 
accordingly until an adequate response was observed. The kinetics of the CS-E 
antibody/CS-E tetrasaccharide interaction was determined by 300 s injections of the CS-E 
antibody at 30 μl/min.  The dissociation was monitored for 900 s before the surface was 
regenerated with a 30 s injection of 6 M guanidine HCl.  The resulting sensorgrams were fit 
to the bivalent analyte model.  Affinity analysis was measured by injecting the antibody for 
3600 s at 5 μl/min.  After 600 s, the surface was regenerated with a 60 s injection at 10 
μl/min.  The data were analyzed by plotting the response at equilibrium versus 
concentration and fitting the resulting curve to the Langmuir equation.  
 
CSPG purification.  Adult brains from Chst15 knockout mice or WT controls were 
dissected and homogenized in PBS with 20 mM EDTA and protease inhibitors (Roche).  
The homogenates were centrifuged at 27,000x g for 1 h at 4 °C.  The supernatant was 
collected, and the pellet was homogenized and centrifuged as before, and the second 
supernatant was added to the first (total volume: 8 ml).  Urea (1 g) was added, and the 
supernatant was incubated at 4 °C for 1 h. For each brain, 2 ml of DEAE Sephacel beads 
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was added to a column, and the supernatant was incubated with these beads for 2 h at 4 °C.  
The column was then drained, and washed with 50 mM Tris HCl, pH 7.5, 2 mM EDTA, 2 
M urea, 0.25 M NaCl.  The CSPGs were eluted with the same buffer, with 0.75 M NaCl.  
The eluate was concentrated using 50 kDa filter columns (Amicon), and dialyzed into PBS.  
Protein concentrations were determined using the carbazole assay with commercial CSPGs 
(Millipore) as a concentration standard. 
 
RhoA activation assay. COS-7 cells were cultured in DMEM supplemented with 10% 
FBS.  The cells were then serum starved overnight, and then the medium was removed and 
replaced with serum-free medium containing CS-E polysaccharides or CSPGs (10 µg/ml). 
After 10 min, the cells were lysed, and RhoA activation was determined using the G-LISA 
kit (Cytoskeleton). 
 
Immunostaining of retinal and optic nerve sections.  At 14 days post-injury, mice were 
given an overdose of pentobarbital and were transcardially perfused with 4% PFA.  
Eyeballs still attached with the optic nerve were dissected and post-fixed in 4% PFA 
overnight.  Following cryoprotection with 30% sucrose in PBS, tissues were embedded in 
O.C.T. and serial sectioned for 10 µm along the longitudinal direction of the nerve.  For 
immunofluorescence labeling, the sections were washed with PBS, pre-incubated in a 
blocking buffer (1% BSA, 0.3% TX-100 in PBS) and followed by sequential incubations 
with primary antibodies, including mouse anti-CS-E (1:200), goat-anti-CTB (1:4,000), or 
rabbit anti-βIII-tubulin antibodies (Invitrogen).  The sections were then reacted with 
biotinylated anti-goat IgG (1:200) and visualized with Alexa Fluor 546-conjugated 
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streptavidin (1:400) or with a Cy3-conjugated goat anti-mouse or -rabbit IgG.  The retinal 
cryosections were mounted with Vectashield and visualized under a Nikon fluorescence 
microscope.  To quantify the number of CTB-positive regenerating axons, the number of 
regenerating axons was counted at 125 μm stepwise from the crush site of the optic nerve.  
To quantify the number of surviving retinal ganglion cells, the total number of βIII-tubulin 
positive cells was counted in at least 3 retinal sections per retina.  
 
Optic nerve regeneration assay.  Immediately after crush injury in the optic nerve of adult 
mice, gelfoam soaked in a solution containing control IgG, CS-E antibody (1.7 mg/ml), 
chondroitinase ABC (ChABC; 50 U/ml), or ChABC (50 U/ml) plus CS-E antibody (1.7 
mg/ml) was placed around the crush site of the nerve and replaced after three days.  To 
analyze whether CS-E contributes primarily to the growth inhibition associated with 
CSPGs and acts extrinsic to neurons to block nerve regeneration, we also compared the 
effects of the CS-E antibody on optic nerve regeneration in vivo with that of CPT-cAMP, 
which is reported to stimulate the intrinsic growth status of retinal ganglion cell axons.  
Thus, in other groups of mice, mice that received an intravitreal injection of CPT-cAMP 
(100 mM, 2 μl) alone or CPT-cAMP plus CS-E antibody (1.7 mg/ml) treatment placed 
around the crush site of the nerve were studied.  To label retinal ganglion cell axons, 2 μl of 
a solution containing an anterograde axon tracer, CTB, was injected intravitreally 3 days 
before mice were sacrificed.  The extent of axonal regrowth was assessed 2 weeks after 
injury. 
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Chapter 4: EphA4 is a Receptor for the Sulfated 
Carbohydrate Epitope CS-E∗
Introduction 
 
The Eph receptors (named after their identification in an erythropoietin-producing 
human hepatocellular carcinoma cell line1) make up a large family of protein-tyrosine 
kinases. These receptors are involved in many different physiological properties, including 
cell patterning,2, 3 guidance,4, 5 attraction,6, 7 and repulsion.8-10 This first member of this 
family was identified over 25 years ago, and is now known as EphA1.11 In the following 
years, multiple ligands for the Eph receptors (termed Eph receptor interacting ligands, or 
ephrins; also referred to as Efns) were discovered.12-14  
Soon after discovery of the first Eph receptor, a role of these proteins in cancer was 
established,15 and this function has been extensively characterized since then. Both the 
ligands and receptors are often present in cancer cells, and changes in their expression 
levels have been linked with cancer progression.16 The receptors and ligands are normally 
bound to the cell membrane, and signals can be transmitted to the cell expressing the Eph  
receptor or the ephrin ligand (“forward” signaling and “reverse” signaling, respectively5, 17-
19). These interactions typically occur at a point where cells are in contact, with the ligand 
and the receptor expressed on opposing cells, i.e. trans interactions; however, some soluble  
                                                 
∗ Surface plasmon resonance (SPR) analysis was performed by Dr. Claude Rogers, a 
former graduate student in the Hsieh-Wilson laboratory. Microarray assays were done in 
collaboration with Dr. BinQuan Zhuang, a former postdoctoral scholar in the Hsieh-Wilson 
laboratory. RT-PCR analysis of DRGs was performed by Gregory M. Miller, a current 
graduate student in the Hsieh-Wilson laboratory. 
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ephrins have been shown to retain their ability to activate their receptors,20, 21 and ephrins 
and Eph receptors on the same cell surface can participate in cis interactions, sending a 
downstream signal in the cell expressing the ligand and the receptor.22, 23 
The Eph receptors are grouped into two categories, based on sequence similarity: 
the EphA and EphB receptors, each with corresponding ligands that generally only 
interact with members of one of the receptor groups. In the human genome, there are nine 
EphA receptors with five ephrin-A ligands, and five EphB receptors with three ephrin-B 
ligands. The binding between the receptors and the ligands is promiscuous; in addition, 
there is some crossover of binding, in which ephrin-A ligands interact with EphB 
receptors, and ephrin-B ligands with EphA receptors.16, 24-26 The ephrin-A ligands are  
 
 
Figure 4.1. The Eph receptors and ephrin ligands. LBD: Ligand-binding domain; FN: Fibronectin; 
SAM: sterile alpha motif; TyrKc: Tyrosine kinase, catalytic; PDZ: PSD95/Dlg/ZO1. 
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linked to the cell surface via a glycosylphosphatidylinositol (GPI) linkage, while the 
ephrin-B ligands contain transmembrane and cytoplasmic regions (Figure 4.1). When 
Eph receptors are engaged by their ligands, autophosphorylation occurs on two tyrosine 
residues that are conserved among the EphA and EphB receptors – Y596 and Y602 in 
EphA4, and Y604 and Y610 in EphB2.27, 28 
EphA and EphB receptors, as well as the ephrin-B ligands, have cytoplasmic 
domains that can initiate internal signaling cascades.29, 30 Since ephrin-A ligands do not 
have cytoplasmic domains, they are dependent upon other membrane proteins that can 
serve as co-receptors for reverse signaling.31-34 One such co-receptor is the p75 
neurotrophin receptor, which was shown to be critical for reverse signaling of ephrin-A3 in 
the retina, forming a complex with ephrin-A3 that is necessary for the repulsive effect 
involved in axon guidance.35 The p75 receptor is also involved in controlling dendrite and 
spine formation and function in hippocampal neurons,36 a biological process that is 
dependent upon Eph-ephrin signaling.37 This apparent convergence in function, as well as 
the p75 receptors’ previously established role in inhibition of neurite outgrowth, 38 makes 
this receptor an intriguing candidate for further study in the context of ephrin signaling. 
The Eph receptors and their ligands play a major role in the formation of the 
nervous system during development. Interactions between the ligands and receptors are 
frequently repulsive, such that cells containing a given Eph receptor are repelled by cells 
containing the ephrin ligand. These repulsive cues are involved in the regulation of axon 
guidance,4, 5 axon fasciculation or bundling,39, 40 formation of topgraphic maps,41, 42 and 
vascularization of the developing nervous system.43, 44 Ephs and ephrins are expressed in 
almost all embryonic tissues,8, 24, 45 highlighting the importance of this group of proteins. 
88 
The Ephs and ephrins are also involved in the maintenance of the nervous system in 
the mature organism, and a role for these proteins has also been established in the 
prevention of regeneration of growth after injury in the nervous system. Members of the 
Eph receptor family, as well as the ephrin ligands, have been shown to be upregulated after 
injury to the adult nervous system.46-48 Ephrin-A ligands and EphA receptors have been 
show to induce growth cone collapse via the activation of Rho and Rho kinase, members of 
a common signaling pathway that is involved in the inhibition of neurite outgrowth.49, 50 
One of the ephrin-B ligands, EphB3, has also been identified as a molecule inhibitory to 
recovery in the CNS after injury.51   
Of particular interest to our group is the receptor EphA4, which has been shown to 
have a role in preventing recovery after spinal cord injury.52 A recent study has shown that 
blocking activity of the EphA4 receptor after spinal cord injury allows axonal regrowth and 
recovery of function.53 Our lab is interested in studying interactions between charged 
carbohydrates and the Eph receptors or ligands, which could potentially cause direct 
activation of receptors, or mediate the interaction between ligands and receptors. Heparan 
sulfate has previously been shown to modulate the interaction between Eph receptors and 
ephrin ligands,54 supporting the possibility of other charged carbohydrates in mediating 
Eph/ephrin interactions.  
In recent years, several receptors for chondroitin sulfate proteoglycans (CSPGs) 
have been discovered,55-57 and our lab has identified CS-E as the crucial motif on CS chains 
that is likely to engage protein receptors.58 Therefore, our lab has focused on targeting the 
Eph receptors and their ligands as potential receptors for the CS-E motif. 
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Results 
EphA4 and Ephrin ligands interact with CS-E. As a general method for identifying 
novel CS receptors, our lab has used affinity chromatography and mass spectrometry to 
find CS-E-interacting proteins in tissues of the nervous system. To do this, we first 
generated affinity columns by immobilizing biotinylated CS-E-enriched or unsulfated CS 
polysaccharides on streptavidin-coated agarose beads. The membrane protein-enriched 
fraction of rat brain lysate was passed over the affinity columns, and bound proteins were 
identified by high-throughput mass spectrometry (LC-MS/MS) analysis. From this 
analysis, EphA4 was identified as a CS-E-interacting protein. Three unique peptides (34 
amino acids, 3% total amino acid coverage) were identified in the pull-down, confirming 
the identity of EphA4 (Figure  4.2).  
 
Figure 4.2. EphA4 peptides identified by LC-MS/MS analysis. EphA4 from rat brain lysates was 
pulled down using CS-E and resolved by SDS-PAGE. In-gel tryptic digestion and LC-MS/MS 
analysis revealed three unique peptides within EphA4. 
 
A commercially available set of EphA Fc chimera proteins containing EphA1, 
EphA2, EphA3, EphA4, EphA5, EphA6, EphA7, and EphA8 was purchased, and these 
proteins were tested on the carbohydrate microarray to screen for binding to CS motifs 
(Figure 4.3).  These results showed that the receptors EphA1, EphA4, and EphA6 show an 
appreciable amount of binding to the CS-E motif, with the strongest binding seen with 
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Figure 4.3. EphA1, EphA4, and EphA6 bind to CS-E on the array. Experiments were repeated in 
triplicate. Representative results are shown. 
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Figure 4.4. EphrinA3, EphrinA5, and EphrinB1 bind to CS-E on the array. Experiments were 
repeated in triplicate. Representative results are shown. 
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 EphA4 and EphA6. A kit containing the soluble portions of the ephrin-A ligands EfnA1, 
EfnA2, EfnA3, EfnA4, and EfnA5, as well as the ephrin-B ligands EfnB1, EfnB2, and 
EfnB3 was also screened (Figure 4.4). These results showed that the ligands ephrin-A3 and 
ephrin-B1 have an appreciable amount of binding to the CS-E motif, with a smaller amount 
of binding observed with ephrin-A5. Additional testing of the EphA4 protein showed that 
the protein binds to both CS-E and a mixed CS preparation containing CS-A, -C, -D, and –
E motifs (Figure 4.5). A small degree of possible binding to heparin and heparan sulfate 
was also observed. 
 
 
 
 
 
 
 
Figure 4.5. EphA4 is specific to CS-E on the microarray. The experiment was repeated three 
times; combined results are shown. Error bars = standard error of the mean for 10 array 
spots per experiment, for three experiments. 
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Figure 4.6. Sensorgram of the interaction of EphA4 with CS-E polysaccharide. EphA4 had a 
dissociation constant of 856 nM. 
 
 
 
 
 
Figure 4.7. Affinity analysis of the ephrin-A3/CS-E polysaccharide interaction gives an apparent KD 
of 65 nM. 
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After screening by microarray, the kinetics of binding between EphA4 and CS-E 
was analyzed by surface plasmon resonance (SPR). EphA4 interacted with CS-E according 
to a one-to-one binding model, with a calculated KD of 856 nM (Figure 4.6). Out of the 
EfnA lignads screened by microarray, EfnA3 appeared to bind to CS-E particularly 
strongly. After performing the SPR analysis, it was found that the interaction between 
EfnA3 and CS-E could not be described using the one-to-one binding model. To obtain an 
overall KD for the interaction, an affinity analysis was performed. EfnA3 was found to bind 
to CS-E with an apparent KD of 65 nM (Figure 4.7).   
Next, expression vectors were constructed containing the entire sequence of 
promising genes of interest: the ligands EfnA3 and EfnB1, and the receptor EphA4. These 
vectors were transfected into cells to express the proteins on the cell surface, and the cells 
were lysed to isolate the expressed proteins. These proteins were then incubated with CS 
that had been biotinylated and conjugated to streptavidin beads. We found that these full-
length constructs were co-precipitated with CS-E, but not other CS motifs (Figure 4.8). The 
receptor EphA4 was co-precipitated only with the CS-E motif, with no observable protein 
capture with the other motifs. The ligands EfnA3 and EfnB1 were also shown to mainly 
interact with the CS-E motif, with minimal interaction with other motifs. However, there is 
some amount of co-precipitation with other CS motifs, suggesting that there may be a small 
amount of non-specific CS binding, which was also seen in the microarray results. In 
experiments that involved co-expressing the proteins, we found that the receptor EphA4 
and the ligand EfnA3 were both co-precipitated by CS-E, allowing the possibility of 
simultaneous ligand-receptor and CS-E interaction.  
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EphA4 is activated in response to CS-E. Next, we sought to determine if activation of the 
EphA4 receptor could be observed in response to CS-E. Engagement with ephrin-A ligands 
causes autophosphorylation of Eph receptors on tyrosine residues, which is the first step 
leading to activation of downstream signaling pathways.19, 26 Since CS-E binds to EphA4, 
and likely has multiple protein binding sites on each molecule, we hypothesized that the 
addition of CS-E to EphA4-expressing cells could induce the oligomerization and 
subsequent phosphorylation of EphA4. To test this hypothesis, EphA4 was overexpressed 
in cells, and CS-E was added to the culturing medium for various amounts of time. 
Figure 4.8. EphrinA3, EphrinB1, and EphA4 are pulled down specifically by CS-E. 
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Afterwards, the cells were lysed, EphA4 was immunoprecipitated, and the enriched EphA4 
protein was assayed for phosphorylation via western blot. We found that CS-E was capable 
of inducing EphA4 phosphorylation (Figure 4.9). The phosphorylation of EphA4 in 
response to CS-E was found to occur in a time-dependent manner, with maximal effects 
observed 15 min after application of CS-E. These levels reduced to control levels after 30 
min. 
 
 
Figure 4.9. Overexpressed EphA4 is phosphorylated in response to CS-E treatment. 
 
 
Abolishment of CS-E expression reduces activity of EphA4 in vivo. In order to further 
determine the effect of CS-E on the EphA4 receptor, we analyzed the endogenous 
phosphorylation of EphA4 in mice deficient in CS-E.59 Adult CS-E KO mice or wild-type 
controls were euthanized, and their hippocampi were extracted and homogenized. This 
homogenate was incubated with EphA4 antibody to enrich the protein, and phosphorylation 
of EphA4 was analyzed via western blot. Our results indicated that basal phosphorylation 
of EphA4 was significantly reduced in the CS-E KO animals, supporting the physiological 
role of CS-E in EphA4 activation (Figure 4.10). 
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Figure 4.10.  Effect of the absence of the CS-E motif on EphA4 phosphorylation in vivo. 
Phosphorylation of endogenous EphA4 in the hippocampus is compared between Chst15 KO (lane 2) 
and control mice (lane 1). Bar graphs represent fold-changes in the intensity of immunoreactive 
bands. Error bars represent standard error of the mean of the relative intensity from six control and 
six knockout mice. *, P < 0.01. 
 
 
CGN Neurite Outgrowth is mediated by Eph receptors. Since EphA4 is expressed in 
many regions of the nervous system during different stages of development,60 we targeted 
several different cell types that could serve as a model for CS-E inhibition in the nervous 
system to be analyzed for involvement of the EphA4 receptor. Using reverse transcriptase 
PCR (RT-PCR) we sought to determine the relative mRNA levels present in postnatal 
cerebellar granule neurons (CGNs), a commonly used neuron type for neurite outgrowth 
experiments, that we previously found to be inhibited in response to CS-E.58 Using this 
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method, we determined that the ligands EfnA1, EfnA3, EfnA5, and EfnB1, and the 
receptor EphA4, were all likely to be expressed based on the presence of their respective 
mRNA (Figure 4.11).  
 
 
 
Figure 4.11. RT-PCR showing the presence of Efn and Ephs in the postnatal cerebellum. 
 
 
After determining the likely expression of Ephs and ephrins in CGNs, we next 
measured CGN neurite outgrowth in response to CS-E, in the presence of dasatinib (BMS-
354825), a tyrosine kinase inhibitor that has been shown to inhibit Ephs.16, 61 We found that 
neurite outgrowth inhibition by CS-E and CSPG in CGNs was rescued when cells were 
cultured with dasatinib added to the medium (Figure 4.12). At 20 nM, dasatinib appeared to 
completely abolish the inhibitory effect of CS-E. The control growth of neurites was 
reduced upon the addition of higher concentrations of dasatinib, however, suggesting that 
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this compound may be somewhat toxic to cells. Furthermore, this molecule is not specific 
to EphA4, allowing for multiple tyrosine kinase receptors being involved in mediating the 
inhibitory signal of CS-E in this cell type. 
 
 
Figure 4.12. Inhibition of CGN neurite outgrowth by CS-E is attenuated by dasatinib. 
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Figure 4.13. CGN neurite outgrowth is inhibited by EfnA3. 
 
We also investigated the effect of the ephrin ligands on neurite outgrowth of CGNs. 
The ligand EfnA3 was coated in the wells of a plastic culture dish, upon which CGNs were 
cultured for 24 h. We found that EfnA3 inhibits the neurite outgrowth of CGNs in a 
concentration-dependent manner (Figure 4.13). Similar experiments were performed with 
EfnA5, and this ligand was found to be a potent inhibitor of CGN outgrowth (Figure 4.14). 
This inhibition was partially overcome upon the addition of KYL, a 12-amino acid peptide 
identified via phage display that binds preferentially to EphA4 compared to other EphA 
receptors, and blocks ephrin binding to the receptor.62, 63 
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Figure 4.14. CGN neurite outgrowth is inhibited by EfnA5, and is reduced with the addition of KYL 
peptide. 
 
We next wanted to see if neurite outgrowth inhibition caused by CS-E and CSPG 
was reduced in cells lacking the EphA4 receptor. CGNs from EphA4 KO mice64 or wild 
type controls were cultured on a substrate of coated CS-E or CSPG. We observed only a 
small degree of possible rescue in the case of CSPG coating, but not with CS-E, suggesting 
other receptors/mechanisms for the inhibition in this cell type (Figure 4.15). Since there 
was only a negligible effect, we reasoned that other receptors expressed in these neurons 
are responsible for mediating the inhibitory effects of CS-E and CSPG. 
102 
 
Figure 4.15. CGN neurite outgrowth inhibition by CSPG is slightly attenuated in EphA4 KO 
neurons, but no difference in CS-E inhibition is observed. *: P<0.005. 
 
Functions of EphA4 and EfnA3 in the developing cortex. We next tested the response 
of cortical neurons, which have high levels of expression of EphA4.60 It was also 
previously shown that the interaction between ephrinA3 and EpA4 in these neurons is 
dependent on heperan sulfate, and this interaction leads to an inhibitory effect.54 We 
found that cortical neurons were highly inhibited by CS-E and CSPG (Figure 4.16), 
making these cells an attractive target for the investigation of the effects of EphA4 and 
CS-E interaction on neuron growth. 
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Figure 4.16. Cortical neurite outgrowth is inhibited by CS-E and CSPG coated on the culture surface 
(left), and by CS-E linked to agarose beads (right). 
 
 
We next tested the phosphorylation of EphA4 in these neurons in response to CS-E. 
These neurons have a very high level of EphA4 expression that is comparable to the 
overexpressed EphA4 described previously, making this measurement feasible in this cell 
type. As with the overexpressed EphA4, the endogenous EphA4 in cortical neurons was 
phosphorylated in response to CS-E treatment in a time-dependent manner (Figure 4.17). 
 
 
 
Figure 4.17. Endogenous cortical EphA4 is phosphorylated in response to CS-E treatment. 
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Next, we tested the effects of Efn ligands in neurons deficient in CS-E.59 We 
reasoned that if CS-E was involved in mediating the interaction of EphA4 and its ligands, 
we should observe less phosphorylation of EphA4 upon addition of ligand in the absence of 
endogenous CS-E. We found that in wild-type neurons, the Efn ligands EfnA2, EfnA3, and 
EfnA5 all resulted in increased phosphorylation of EphA4, as expected (Figure 4.18). 
However, we were surprised to observe that in the CS-E KO neurons, the activation 
induced by EfnA3 and EfnA5 was increased, suggesting a higher degree of activation of 
the receptor by its ligands when CS-E is absent. Because CS-E binds to both the EphA4 
receptor and the EfnA3 and EfnA5 ligands, it is possible that CS-E serves to sequester the 
proteins away from each other in this cell type. Activation of EphA4 in response to the 
EfnA2 ligand, which was not found to bind to CS-E in our array screening, was similar in 
the wild-type and CS-E KO neurons.  
 
 
Figure 4.18. Activation of EphA4 in response to Efn ligands in CS-E +/+ (top) and CS-E -/- (bottom) 
cortical neurons. The average of three experiments is shown. 
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Figure 4.19. No difference in CS-E inhibition is observed in cortical neurons deficient in EphA4. The 
results of three experiments are shown, >300 neurons per experiment. Error bars represent standard 
error of the mean (SEM) for all neurons. 
 
We next wanted to see if neurite outgrowth inhibition by CS-E and CSPG was 
rescued in cells lacking the EphA4 receptor. Cortical neurons from EphA4 knockout mice 
or wild type controls were cultured on a substrate of coated CS-E. We found that there was 
no rescue of outgrowth in the KO neurons, which showed the same degree of inhibition as 
seen in the control (Figure 4.19). This result suggests that EphA4 is not primarily 
responsible for CS-E inhibition in cortical neurons.  
We next sought to investigate the possible role of EfnA3 in these neurons, using 
mice deficient in this protein.65 As this ligand bound very strongly to CS-E via microarray 
and SPR analysis, we reasoned that neurons lacking this protein might show some 
difference in response to CS-E. EfnA3 was also an intriguing target for analysis, as it has 
been found to be crucial for biological functions in conjunction with EphA4, such as spine 
morphology.37, 65 Cortical neurons from EfnA3 knockout mice or wild type controls were 
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cultured on a substrate of coated CS-E, as with the EphA4 KO neurons. We found that the 
neurons deficient in EfnA3 were much less inhibited that the control (Figure 4.20). As 
mentioned previously, EfnA3 (and other EfnAs) are not independently capable of 
transmitting inhibitory signals, as they lack an intracellular domain. However, this result 
shows a strong role for EfnA3 in CS-E-mediated inhibition in cortical neurons, and further 
studies may reveal the critical co-receptor for this effect. 
 
 
Figure 4.20.  Significant rescue of CS-E inhibition is observed in cortical neurons deficient in EfnA3. 
The results of three experiments are shown, >300 neurons per experiment. Error bars represent 
standard error of the mean (SEM) for all neurons. Statistical analysis was performed using the one-
way ANOVA (*P < 0.001, relative to control).   
 
DRG Neurite Outgrowth is mediated by EphA4 and the ligand EfnA3. Next, we 
investigated dorsal root ganglion (DRG) neurons, which allow us to approximate the 
growth conditions of the spinal cord in vitro. As EphA4 and CS have both been previously 
shown to be involved in the inhibition of recovery after spinal cord injury, we reasoned that 
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the observed interaction between these two molecules may be able to explain the effect. 
Using RT-PCR we determined the relative mRNA levels of both EphA4 and EfnA3 present 
in postnatal DRGs, and found that both EphA4 and EfnA3 are likely to be expressed in 
both pup and adult DRGs based on the presence of their mRNA (Figure 4.21). 
 
 
 
Figure 4.21. EphA4 and EfnA3 are expressed in postnatal mouse DRGs. For each pair, cDNA from 
P7 pups (left) and adult (right) were used. 
 
 
 
 
 
Although the neuron-bound Eph receptors typically interact with ephrins expressed by glial 
cells, we hypothesized that the EphA4 and EfnA3 expressed by DRGs could be inhibiting 
cellular growth by interacting with CS-E, either separately or cooperatively. To determine 
the role of EphA4 and EfnA3 in DRG outgrowth, we measured the outgrowth of neurons 
deficient in either protein in the presence of CS-E. Deletion of EphA4 significantly 
attenuated CS-E-induced inhibition of neurite outgrowth (Figure 4.22), indicating that 
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EphA4 is required for CS-E to inhibit neurite outgrowth. Interestingly, deletion of EfnA3 
also significantly attenuated CS-E-induced inhibition of neurite outgrowth (Figure 4.23), 
suggesting that these proteins are both involved in mediating the inhibitory signal of CS-E 
in this cell type.  
 
Figure 4.22. Inhibition of DRG neurite outgrowth by CS-E is attenuated in EphA4 KO neurons. The 
results of three experiments are shown, >300 neurons per experiment. Error bars represent standard 
error of the mean (SEM) for all neurons. Statistical analysis was performed using the one-way 
ANOVA (*P < 0.005, relative to control). 
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Figure 4.23. Inhibition of DRG neurite outgrowth by CS-E is attenuated in EfnA3 KO neurons. The 
results of three experiments are shown, >300 neurons per experiment. Error bars represent standard 
error of the mean (SEM) for all neurons. Statistical analysis was performed using the one-way 
ANOVA (*P < 0.005, relative to control). 
 
 
Conclusions 
Previous evidence has shown that the EphA4 receptor has various roles in the 
development and regulation of the nervous system, and plays a role in inhibiting regrowth 
after injury in the adult. We found that EphA4 binds directly and with high affinity to CS-E 
to operate as a receptor for this sulfated motif. Our results support the role of EphA4 in 
mediating the inhibition of axon outgrowth in DRG neurons, which replicate the growth 
conditions of the spinal cord. EphA4 deletion in transgenic mice promotes significant 
neurite and axon outgrowth in mature DRG neurons cultured on CS-E substrates.  
Furthermore, we have found that EfnA3, a ligand for EphA4, also binds directly 
and with high affinity to the CS-E motif, and has a crucial role for the inhibition caused by 
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CS-E in cortical neurons and in DRGs. In DRGs, both the ligand and the receptor are 
critical for CS-E interaction, suggesting that they are both interacting on these cells, in an 
example of cis Eph activation. In cortical neurons, EfnA3 seems to be mediating the effect 
independently of EphA4, either via other EphA receptors or through another unidentified 
co-receptor.  
The identification of a novel protein that mediates the inhibitory effect of CS-E 
advances our understanding of inhibition after injury in the CNS when CS-E expression is 
upregulated, and provides us with the opportunity to develop therapies for the recovery of 
axonal outgrowth after damage to the nervous system. Future work in our lab will explore 
the molecular basis of interactions between CS-E and the EphA4 receptor and EfnA3 
ligand. The identification of a specific site on these proteins that binds CS-E may provide 
leads for potential drug design to treat spinal cord injury. Alternative blocking approaches 
targeting the CS motifs, such as the CS-E antibody, could be used, and such approaches 
could potentially be combined with blocking agents of other regeneration inhibitors. 
Identifying a receptor for the inhibitory CS-E motif provides new pathways for research 
into mechanisms and therapeutic interventions to enhance regeneration after nervous 
system injury. 
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Materials and Methods 
Mass spectrometry analysis. Brains were dissected from P7-P9 Sprague Dawley rats, 
homogenized in 0.32 M sucrose with protease inhibitors (Roche), and centrifuged at 1,000 
g for 10 min.  The supernatant was collected, and then centrifuged at 10,000 g for 20 min.  
The pellet was discarded, and the supernatant was centrifuged again at 12,000 g for 30 min.  
This supernatant was then ultra-centrifuged at 200,000 g for 1 h, and the pellet was saved 
and homogenized again in 0.32 M sucrose with protease inhibitors.  The supernatant was 
again ultra-centrifuged at 200,000 g for 1 h and the pellet was saved, solubilized in 1% 
Triton X-100 (PBST) with protease inhibitors, and centrifuged at 12,000 g for 15 min.  The 
final supernatant was obtained as the membrane protein-enriched fraction and incubated 
with CS-E or unsulfated CS conjugated to streptavidin agarose resin (described above) 
overnight at 4 ºC.  The resin was washed with PBS, and the PBS was collected and 
measured until the OD280 was less than 0.05.  The bound proteins were then eluted with 
PBS containing 500 mM NaCl.  The eluted proteins were then dialyzed into PBS and 
subjected to SDS-PAGE.  The resulting gel was stained with Coomassie Brilliant Blue, and 
the band at 206 kDa was cut out, subjected to tryptic digestion, and analyzed by liquid 
chromatography–mass spectrometry (LC-MS) analysis as reported.68  
Microarray assays. Microarrays were generated as described previously.69 Arrays were 
blocked with 10% FBS in PBS with gentle rocking at 37 °C for 1 h, followed by a brief 
rinse with PBS. Fc chimera proteins (R & D Systems) were reconstituted in 1% BSA in 
PBS, added to the slides in 100 µl quantities at a concentration of 250 nM, and incubated at 
room temperature for 3 h.  The slides were briefly rinsed three times with PBS, and then 
incubated with a goat anti-human IgG antibody conjugated to Cy3 (Jackson 
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ImmunoResearch; 1:5,000 in PBS) for 1 h in the dark with gentle rocking, and scanned at 
532 nm using a GenePix 5000a scanner.  Fluorescence quantification was performed using 
GenePix 6.0 software (Molecular Devices).  Experiments were performed in triplicate, and 
the data represent the average of 10 spots per concentration averaged from the three 
experiments (± SEM, error bars). 
Molecular Cloning. EphA4, EfnA3, and EfnB1 genes were subcloned from mouse cDNA 
(Open Biosystems) into a pCAX Myc6 vector using the restriction enzymes FseI (N-
terminal) and AscI (C-terminal) to place an N-terminal 6X Myc tag on the expressed 
proteins. The vector contained a secretion peptide coding sequence upstream of the myc 
tag; thus, the endogenous signal peptide coding sequences were excluded from the cloning 
sequence.  
 
EphA4 sense primer: AATGCTGGCCGGCCAGTCACCGGTTCTAGGGTATACCCC 
EphA4 antisense primer: ATTGGCGCGCCTCAGACAGGAACCATCCTGCCATG 
EfnA3 sense primer: AATGCTGGCCGGCCACAGGGGCCTGGGGGCGCACTGGGA 
EfnA3 antisense primer: ATTGGCGCGCCCTAGGAGGCCAAGAGCGTCATGAG 
EfnB1 sense primer: AATGCTGGCCGGCCAAAGAACCTGGAGCCCGTGTCCTGG 
EfnB1 antisense primer: ATTGGCGCGCCTCAAACCTTGTAGTAGATGTTCGC 
 
RT-PCR. Total RNA was prepared from P7 or adult (~6 weeks old) mouse tissues using 
the RNeasy Mini Kit (Qiagen). First-strand cDNA was synthesized using iScript cDNA 
synthesis Kit (Bio-rad). 1 μg of total RNA, 4 μl of 5x iScript reaction mix and 1 μl iScript 
reverse transcriptase were mixed together and adjusted to a total volume of 20 μl with 
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nuclease-free water. The reaction mixture was incubated at 25 °C for 5 min, followed by 
incubation at 42 °C for 30 min and, finally, at 85 °C for 5 min. The reaction mixture was 
diluted 1:10 with nuclease-free water. PCR was carried out using One Taq Hot Start DNA 
Polymerase (New England Biolabs) for 30 cycles. A first round of PCR was performed 
using the first round primer sets. 2 μl of cDNA, 5 μl of OneTaq standard reaction buffer, 
0.5 μl of 10mM dNTPs, 0.5 μl of each 10 μM forward and reverse primer solutions and 
0.125 μl One Taq Hot Start DNA Polymerase were mixed and adjusted to a total volume of 
25 μl. A second round of PCR was performed using the second round primer sets. 10 μl of 
template DNA from round 1, 10 μl of OneTaq standard reaction buffer, 1 μl of 10mM 
dNTPs, 1 μl of each 10μM forward and reverse primer solutions and 0.25 μl One Taq Hot 
Start DNA Polymerase were mixed and adjusted to a total volume of 50 μl. Samples were 
analyzed using electrophoresis on a 2% (w/v) agarose gel containing ethidium bromide. 
 
First round: 
EphA1 sense primer: 5’-ATGGAGCGGCGCTGGCCCCTGGGG-3’ 
EphA1 antisense primer: 5’-CTCTCCTCCGGTCAGGCTTCTGGA-3’ 
EphA4 sense primer: 5’-ATGGCTGGGATTTTCTATTTCATC-3’ 
EphA4 antisense primer: 5’-AGTGGAGTTGGCTCCATCGCCAAT-3’ 
EphA6 sense primer: 5’-ATGCAATTCCCCTCGCCTCCAGCC-3’ 
EphA6 antisense primer: 5’-AATCTGCCCTTGTTCTGCCGCCAT-3’ 
EphB6 sense primer: 5’-ATGGCTACTGAGGGCACGACTGGC-3’ 
EphB6 antisense primer: 5’-CACCAAGGACAGCTTCTCTGGAAG-3’ 
EfnA1 sense primer: 5’-ATGGAGTTCCTTTGGGCCCCTCTC-3’ 
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EfnA1 antisense primer: 5’-TCACTGAGATTGCAGCAGCAGCAG-3’ 
EfnA3 sense primer: 5’-ATGGCGGCGGCTCCGCTGCTGCTG-3’ 
EfnA3 antisense primer: 5’-CTAGGAGGCCAAGAGCGTCATGAG-3’ 
EfnA5 sense primer: 5’-ATGTTGCACGTGGAGATGTTGACG-3’ 
EfnA5 antisense primer: 5’-CTATAATGTCAAAAGCATCGCCAG-3’ 
EfnB1 sense primer: 5’-ATGGCCCGGCCTGGGCAGCGTTGG-3’ 
EfnB1 antisense primer: 5’-GTCCCCGCTGCCACCGCCACCTGC-3’ 
 
Second round: 
EphA1 sense primer: 5’-CTTGCATTGCTGCTGCTGCTGCTC-3’ 
EphA1 antisense primer: 5’-AACTGGTGGGCTTGTCCGAAACTC-3’ 
EphA4 sense primer: 5’-CTCTTTTCGTTTCTCTTTGGAATT-3’ 
EphA4 antisense primer: 5’-GATGCGGGAAGGCACTGTATTAGT-3’ 
EphA6 sense primer: 5’-GCCAGGAGCTCCCCGGCGGCGCAG-3’ 
EphA6 antisense primer: 5’-GTCAGAAGTTTCATCTCCTGTTTC-3’ 
EphB6 sense primer: 5’-TCAGGGAGCAGAGTGGTGGCGGGC-3’ 
EphB6 antisense primer: 5’-CTGGGAGGACAGCTCACCTTGAGG-3’ 
EfnA1 sense primer: 5’-TTGGGTCTGTGCTGCAGTCTGGCC-3’ 
EfnA1 antisense primer: 5’-TGGTAGGAGCAATACTGCCCAGAC-3’ 
EfnA3 sense primer: 5’-CTGCTGCTGCTGCTGCTCGTGCCC-3’ 
EfnA3 antisense primer: 5’-GAAGAAGGCGATGCCCACGGCCAG-3’ 
EfnA5 sense primer: 5’-CTGCTCTTTCTGGTGCTCTGGATG-3’ 
EfnA5 antisense primer: 5’-GAGGAACAGTAGGATTGCCAAAAG-3’ 
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EfnB1 sense primer: 5’-CTCAGCAAGTGGCTTGTGGCTATG-3’ 
EfnB1 antisense primer: 5’-ACCTGGGCCACTCTTCTCTTCCTG-3’ 
 
Immunoprecipitation. COS-7 cells were transfected with constructed vectors using 
Lipofectamine (Invitrogen) and lysed two days after transfection with 1% Triton X-100 in 
PBS containing a protease inhibitor cocktail (Roche).  Lysates were then incubated with 
streptavidin agarose resin (Pierce; 30 µl) with end-over-end mixing for 1 h at 4 °C to 
reduce nonspecific binding.  The supernatant was collected, added to 30 µl of either CS-C 
or CS-E streptavidin agarose resin, and incubated with end-over-end mixing for 4 h at 4 °C.  
The supernatant was removed, and the resin was washed three times with PBS (500 µl).  
Resin was boiled with 2X loading dye (30 µl of 100 mM Tris, 200 mM DTT, 4% SDS, 
0.10% bromophenol blue, 20% glycerol), and the eluate was resolved by SDS-PAGE and 
transferred to PVDF membrane.  Proteins were detected by immunoblotting with an anti-
myc antibody (Cell Signaling) following the manufacturer’s protocol.   
Cellular Culture.  For assays using CGNs, Poly-D-Lysine Cellware plates were coated 
with laminin (10 µg/ml) in Neurobasal medium (Invitrogen) for 2 h at 37 °C and 10% CO2. 
Cerebella were dissected, incubated in 0.125% trypsin w/ EDTA for 10 min at 37 °C, 
triturated to dissociate to single cell suspensions, purified on discontinuous 35%/60% 
Percoll gradient, and cultured on the coated coverslips in Neurobasal medium 
supplemented with B27, GlutaMAX™ (Invitrogen), and 40 ng/ml bFGF (R&D) at a 
density of 25,000 cells/well for 24 h. Cells were fixed in 4% PFA with 10% sucrose, 
immunostained using an anti-β tubulin III antibody (TUJ1; Covance), imaged using a 
Nikon TE2000-S fluorescent microscope and quantified using the NIH software ImageJ. 
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Statistical analysis was performed using the one-way ANOVA; n = 50–200 cells per 
experiment, and results from at least three independent experiments were reported. For Efn 
inhibition studies, Ephrin ligand was coated on Poly-D-Lysine Cellware plates (500 
ng/well) overnight at 37 °C and 10% CO2. Laminin was added (10 µg/ml) in Neurobasal 
medium (Invitrogen) for 2 h at 37 °C, and CGNs were cultured for 24 h.  KYL peptide 
(KYLPYWPVLSSL) was synthesized by GenScript USA Inc., and was added to the 
culture medium at the start of culturing (10 µM). 
For inhibition studies using DRG neurons from EphA4-/- and EfnA3-/- mice, Poly-D-
Lysine Cellware Plates were coated with laminin (10 µg/ml) in Neurobasal medium 
(Invitrogen) for 2 h at 37 °C and 10% CO2.  DRGs were dissected from adult knockout 
(KO) mice or WT controls, incubated in 0.125% trypsin w/ EDTA for 15 min at 37 °C, 
followed by collagenase (Worthington; 4 mg/ml) for 15 min at 37 °C, triturated to 
dissociate to single cell suspensions, filtered using a 40-µm cell strainer (Fisher) to remove 
non-dissociated cells, and seeded at approximately 2,000 cells per well.  Cells were 
cultured for two days in Neurobasal medium supplemented with B27 and GlutaMAX™ 
(Invitrogen).  CS-E was biotinylated as described70 and conjugated to streptavidin agarose 
beads (200 µg of CS in 400 µl PBS incubated with 100 µl agarose resin for 1 h at room 
temperature), which were then co-plated with the cells (5 µg of 50% slurry per well).  
Unconjugated beads at the same concentration were used as a control.  Cells were grown in 
Neurobasal medium supplemented with B27 and GlutaMAX™ (Invitrogen) for two days.  
For all neurite outgrowth experiments, we performed statistical analysis using the one-way 
ANOVA; n = 50-200 cells per experiment, and results from at least three independent 
experiments were reported. 
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For cortical neuron experiments, Poly-D-Lysine Cellware plates were coated with laminin 
(10 µg/ml) in Neurobasal medium (Invitrogen) for 2 h at 37 °C and 10% CO2.  Pregnant 
E16 EphA4-/- and EfnA3-/- knockout (KO) mice or WT controls were euthanized, and 
embryos were extracted into cold HBSS. The brains were removed from the embryos, and 
the cortices were separated from the rest of the tissue. Meninges were carefully removed, 
and the cortices were incubated in trypsin (Life Technologies) at 37 °C for 15 min. Tissue 
was quenched with DMEM with 10% FBS, pelleted, and resuspended in DMEM with 10% 
FBS. The tissue was triturated to dissociate to single cell suspensions, filtered using a 40-
µm cell strainer (Fisher) to remove non-dissociated cells, and seeded at approximately 
20,000 cells per well.  Cells were cultured for 24 h in Neurobasal medium supplemented 
with B27 and GlutaMAX™ (Invitrogen). For activation assays, neurons were dissected as 
described above, and cultured in 10 cm dishes (~10 million cells/dish). 
Immunostaining and quantification.  All neuronal cultures were fixed with 
paraformaldehyde, permeabilized with 0.1% Triton X-100 in PBS, blocked with 1% BSA 
in PBS, and incubated with a mouse anti-βIII tubulin antibody (Sigma) overnight at 4 °C, 
followed by an Alexa Fluor 488-conjugated goat anti-mouse IgG secondary antibody 
(Invitrogen) for 1-2 h at room temperature for neurite outgrowth assays.  Cells were imaged 
using a Nikon TE2000-S fluorescent microscope or Zeiss LSM Pascal, and neurite 
outgrowth was quantified using NIH software ImageJ or MetaMorph software.  Statistical 
analysis was performed using the one-way ANOVA; n = 50-500 cells per experiment, and 
results from at least three independent experiments were reported. 
Activation Assays. COS-7 or HEK293T cells were transfected with EphA4 using 
Lipofectamine (Life Technologies). Cells were cultured for two days in DMEM 
118 
supplemented with 10% FBS. For cortical activation assays, cortical neurons were 
dissected and cultured as described above. After 24 h, cells were stimulated by changing 
their medium to fresh medium containing CS-E (Seikagaku; 10 µg/ml) or Efn-Fc proteins 
(R&D systems; 1 µg/ml) and incubating for the time described at 37 °C. Cells were lysed 
with cold lysis buffer consisting of PBS with 1% Triton X-100 with protease inhibitor 
cocktail (Roche) and phosphatase inhibitor mixture. Lysates were clarified via 
centrifugation. For each sample, 50 µl of protein A/G agarose (Pierce) was added to an 
Eppendorf along with 3 µg of EphA4 antibody (Invitrogen). Clarified lysate was added, 
and incubated at 4 °C with rotation for 2 h. Agarose was washed three times with lysis 
buffer, boiled with 2X loading dye (30 µl of 100 mM Tris, 200 mM DTT, 4% SDS, 0.10% 
bromophenol blue, 20% glycerol), and the eluate was resolved by SDS-PAGE and 
transferred to PVDF membrane.  Phosphorylated EphA4 was detected by immunoblotting 
with an anti-phosphotyrosine antibody (BD Biosciences) following the manufacturer’s 
protocol.  After scanning, membranes were stripped (NewBlot 5X PVDF stripping buffer; 
LI-COR) and re-blotted with anti-EphA4 antibody (Invitrogen). For analysis of Jak2/Stat1 
phosphorylation, COS-7 cells were transfected with EphA4 expression vector, and cultured 
for two days in DMEM supplemented with 10% FBS. After two days, cells were serum-
starved by culturing in DMEM with 0.5% FBS for 6 h. After serum starvation, cells were 
stimulated with CS-E or other molecules in reduced-serum medium as indicated. The cells 
were then lysed with RIPA buffer (25 mM Tris-HCl, pH 7.6; 150 mM NaCl; 1% NP-40; 
1% sodium deoxycholate; 0.1% SDS; protease and phosphatase inhibitor cocktail) and 
sonicated. The lysed were clarified by centrifugation at 12,000 rpm for 4 min. Loading dye 
was added to the lysate, and the lysate was resolved by SDS-PAGE and transferred to 
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PVDF membrane.  Phosphorylated Jak2 and Stat1 were detected by immunoblotting with 
an anti-phosphotyrosine Jak2 antibody (Millipore) or anti-phosphotyrosine Stat1 antibody 
(Cell Signaling) following the manufacturer’s protocol.  After scanning, membranes were 
stripped (NewBlot 5X PVDF stripping buffer; LI-COR) and re-blotted with anti-Jak2 or 
Stat1 antibodies (Santa Cruz).  
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Appendix 1: The myelin protein inhibitors and their 
receptors interact with CS-E∗
Introduction 
 
Following injury to the central nervous system (CNS), a variety of inhibitory 
molecules prevent neuronal regeneration. These inhibitory molecules exist in two 
categories: the myelin-associated inhibitory proteins and proteoglycans associated with the 
glial scar.1-4 There are several myelin-associated proteins involved in inhibiting neuronal 
growth after injury to the central nervous system, including the reticulon protein Nogo-A, 
myelin-associated glycoprotein (MAG), and oligodendrocyte myelin glycoprotein (OMgp), 
all of which converge on common receptors.4 One of the first receptors identified for these 
inhibitory proteins is the Nogo-66 receptor5 (NgR), which binds Nogo-66, a 66-amino acid 
loop near the C-terminal region of Nogo-A which is expressed on the neuronal cell surface. 
It was later found that MAG and OMgp are also ligands for this receptor.4, 6, 7 NgR is linked 
to the cell surface via a glycosylphosphatidylinositol (GPI) anchor at its C-terminus, and 
thus must form a receptor complex with a transmembrane protein in order to transmit its 
inhibitory signal. This critical co-receptor was identified as the p75 neurotrophin receptor8 
(p75NTR/p75). This NgR/p75 receptor complex was later found to also include Lingo-1,  
 
                                                 
∗ Experiments using signaling molecule inhibitors were performed by Dr. Cristal Gama, a 
former graduate student in the Hsieh-Wilson laboratory. Surface plasmon resonance 
(SPR) analysis was performed by Dr. Claude Rogers, a former graduate student in the 
Hsieh-Wilson laboratory. 
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and these three proteins together are sufficient to transmit the inhibitory signal of Nogo-66, 
MAG, and OMgp.9 It was later discovered that the more broadly expressed TNF receptor 
TAJ/TROY could replace p75 in this complex, and may be more likely to be found in the 
complex at later developmental stages, when it is more highly expressed compared to 
p75.10 Furthermore, a recent study showed that the mostly uncharacterized protein Amigo3 
can substitute for Lingo1 in the complex, and is upregulated soon after injury (compared to 
the delayed upregulation of Lingo1) supporting a functional role for this protein in 
inhibiting growth after injury.11  
 
 
Figure A1.1. Myelin-associated inhibitors and their receptor(s). Nogo-66, MAG (myelin-associated 
glycoprotein) and OMgp (oligodendrocyte myelin glycoprotein) all bind to NgR with high affinity. 
NgR associates with transmembrane coreceptors to transduce the signal across the plasma 
membrane. Nogo-66 and MAG also bind to PirB (paired immunoglobulin-like receptor B), while 
MAG also binds to the ganglioside GT1b. 
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An additional recognition element, the ganglioside GT1b, was also found to 
associate with the inhibitory protein MAG, and it was further found that GT1b associates 
with the p75 receptor to form a complex to transmit the inhibitory signal from MAG.12, 13 
Finally, a novel receptor, PirB, was recently discovered as a binder and mediator of the 
inhibitory signal of both MAG and Nogo-66.14 It was later found that the p75 receptor is 
required for the inhibitory signaling of PirB, highlighting the seemingly crucial role of this 
protein in mediating the inhibitory signaling of the myelin inhibitory proteins.15  These 
ligand and receptor interactions described above are summarized in Figure A1.1. 
In the NgR receptor complex, NgR alone has been shown to be the critical binding 
element which binds to the ligands Nogo-66, MAG, and OMgp, while the other 
components are needed for signaling and do not seem to engage the ligands.9 Upon ligand 
binding to the NgR receptor complex, Rho and Rho-kinase (ROCK) are activated to trigger 
actin depolymerization, which ultimately leads to growth cone collapse and the inhibition 
of neurite outgrowth.2, 16 Further demonstrating the effect of this receptor complex, neurons 
from mice deficient in p75 show reduced inhibition of neurite outgrowth by the myelin 
inhibitory proteins.8 
Until recently, receptors mediating the effect of the second group of inhibitory 
molecules, the proteoglycans, were unknown. However, in the last several years, specific 
receptors involved in CSPG-mediated axon inhibition after CNS injury have been 
identified.17-19 Our lab has shown that a specific CS motif, CS-E, serves as a recognition 
element to facilitate interactions of CSPGs with inhibitory receptors (see Chapters 3 and 4).  
As a general approach to learn about the downstream pathways mediating this inhibition, 
and to establish a role for receptors in mediating this effect, our lab cultured neurons on 
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CSPG or CS-E polysaccharides with or without inhibitors to various downstream signaling 
molecules. These included inhibitors to Rho/Rho-kinase (ROCK; Y27632), mitogen-
activated protein kinase (MEK; PD98059), and epidermal growth factor receptor (EGFR; 
AG1478), all of which have been shown to be activated by CSPGs and myelin inhibitors.16, 
20-22 As a control, an inhibitor to JNK (JNK inhibitor II) was also included (Figure A1.2). 
As shown in the figure, ROCK, MEK, and EGFR are involved in mediating the inhibitory 
signal of both CSPG and CS-E, as inhibiting these molecules reduces the inhibitory effect 
on neurite outgrowth. Thus, proteins known to activate these signaling molecules are likely 
candidates for CSPG receptors, which specifically engage the CS-E motif. 
 
 
Figure A1.2. Inhibitors to MEK, EGFR, and ROCK, but not Jnk, attenuate the inhibitory effects of 
both CSPG and CS-E, to a similar degree. (A) Inhibitors to MEK, EGFR, ROCK, and JNK alone 
have no effect on CGN outgrowth.  Dissociated rat P5-9 CGN neurons were cultured on a P-Orn 
substratum in the presence or absence of inhibitors against MEK (PD98059, 25 µM), EGFR 
(AG1478, 15 nM), ROCK (Y27632, 5 µM), and JNK inhibitor II (10 µM) for 24 h. Neurites were 
visualized by staining with an anti-β-tubulin III antibody, and quantification from at least three 
independent experiments is reported (n = 50–200 cells per experiment). 
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Results 
Interestingly, the signaling molecules ROCK, MEK, and EGFR are involved in the 
inhibitory signaling of both the myelin inhibitors Nogo-66, MAG, and OMgp as well as 
CSPGs and CS-E.2, 4, 20, 21 Because of this convergence of signaling molecules, it is possible 
that there is also a convergence in the receptors mediating this signal. Our lab first targeted 
the NgR receptor complex, as this complex mediates the signal of all three myelin 
inhibitory proteins. To investigate possible interactions between proteins in this complex 
and chondroitin sulfate, we first tested the binding of the receptor proteins that were 
available as soluble, Fc hybrid proteins to various CS motifs first via microarray assay to 
look for evidence of interactions. We found that soluble NgR Fc-fusion protein selectively 
binds to CS-E on the microarray, while an Fc control protein did not show any binding 
(Figure A1.3). 
 
 
Figure A1.3. Representative portions of microarrays tested with NgR (left) or Fc control (right). 
 
NgR-Fc and p75-Fc were also tested to determine the relative binding of each of 
these components of the receptor complex. The experiments were repeated five or six times 
(p75 and NgR, respectively) and each experiment yielded binding data for 10 spots of each 
polysaccharide at each concentration. Graph bars represent all spots from all array 
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experiments for the shown concentrations. For each microarray experiment, values were 
normalized relative to the highest binding signal for that particular array, and these results 
were averaged to produce the final result. This interaction appears to be selective to CS-E, 
as minimal binding was observed to other highly sulfated GAGs such as heparin and 
heparan sulfate. Although both proteins specifically bind CS-E, the interaction between 
CS-E and NgR was greater than that of CS-E and p75 (Figure A1.4). 
 
 
Figure A1.4. NgR and p75 bind preferentially to CS-E enriched polysaccharides on the microarray. 
Comparitive binding of NgR and p75. Each bar represents the average of ten spots on one typical 
array. The binding intensity is relative to that of NgR binding to 5µM CS-E. 
132 
 
Figure A1.5. Myelin inhibitory proteins (left) and associated receptors (right) on the carbohydrate 
microarray. Amino Nogo, Nogo-66, and OMgp selective bid to CS-E, compared to other CS motifs. 
MAG did not bind to any motifs. All of the receptors tested (p75, TAJ/TROY, and NgR) selectively 
bound to the CS-E motif. The lower right shows the comparative binding of all proteins to CS-E.  
  
 
After determining that both NgR and p75 seemed to bind specifically to CS-E, 
additional available myelin inhibitory ligands or receptors were tested. Of the myelin 
protein ligands, we found that amino Nogo/NiG (a region of the NogoA protein that is 
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inhibitory to neurite outgrowth and acts via RhoA activation, but is independent of the 
NgR/p75 receptor complex23), Nogo-66, and OMgp all bound preferentially to the CS-E 
motif, compared to other CS motifs (Figure A1.5).  MAG did not bind to any of the CS 
motifs on the array, and in fact appeared to display repulsion to the CS spots on the surface, 
which is indicated by a negative value in the graph. MAG has a lower theoretical isoelectric 
point, calculated based on amino acid sequence, and thus is expected to have a net negative 
charge at physiological pH which causes it to be repelled by the negatively charged CS on 
the microarray surface. 
Of the receptors tested, p75, TAJ/TROY, and NgR all appeared to preferentially 
bind CS-E, with little or no binding to the other CS motifs. Figure A1.5 shows a scaled 
graph comparing the relative binding of each of the proteins tested to CS-E. NgR in 
particular bound to CS-E to a very high degree, and most of the other proteins demonstrate 
some level of affinity for the CS-E motif.  This high level of binding of CS-E by the 
soluble NgR-Fc protein was further demonstrated by surface plasmon resonance (SPR). 
Kinetic analysis using SPR revealed that NgR binds to CS-E polysaccharides with 
remarkably high affinity and specificity (Figure A1.6). At least two independent, high-
affinity NgR binding sites were observed within CS-E polysaccharides (KD1 = 8.7 nM; 
KD2 = 1.8 pM), whereas binding CS-C polysaccharides was not detected. 
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Figure A1.6. Kinetic analysis of NgR-binding to CS-E-enriched polysaccharides by surface plasmon 
resonance. (A) Biotinylated CS-E polysaccharides were immobilized onto the surface via streptavidin 
capture (RL = 25 RU). NgR was passed over the surface at 80 µL/min at 25 ºC for 240 s. After 
monitoring the dissociation for 600 s, the surface was regenerated by three successive injections of 2.5 
M MgCl2 of 90 s at 30 µL/min. The resulting sensorgrams were fit to the heterogeneous ligand model 
(black lines), where the bulk refractive index (RI) was set as a constant value of zero. The model 
predicts two independent binding sites. The kinetic parameters derived from the fitting are tabulated 
in (C), with the standard error in parentheses. (B) Simulation of curves representing the individual 
binding components of the heterogeneous ligand model. A binding site with picomolar affinity (solid 
lines) binds approximately 6 molecules of NgR per polysaccharide, based on solving the equation 
Rmax = RL(MWA/MWL)Sm for Sm, the number of binding sites. The observed nanomolar binding site 
(dashed lines) binds approximately 2 molecules of NgR per polysaccharide. (D) No binding of NgR to 
CS-C polysaccharides was observed (black line). 
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This specific binding of the receptor protein ectodomains to CS-E on the 
microarrays gave the first possible indication that these proteins could serve as a receptor 
for CS-E and thus for CSPG. However, these soluble proteins represent only a portion of 
the total protein, and lack the C-terminal end of NgR and the transmembrane and 
intracellular portions of p75. Additionally, several of the myelin inhibitory proteins were 
not commercially available as soluble proteins, and thus need to be cloned and expressed. 
The next step was to confirm the microarray binding results by testing for specific binding 
to CS-E with the native, full-length proteins. We generated full-length expression vectors 
for NgR and p75, as well as the receptors Lingo-1 and PirB, which were not available as 
soluble fusion proteins for testing on the array.  These constructs were transfected into 
COS-7 cells, which were later lysed to solubilize membrane proteins.  
 
After establishing expression of the full-length proteins, the next step was to try to 
confirm the specific binding to CS-E as seen with the microarrays, using CS that had been 
biotinylated as described previously.24 This technique yields a one-to-one ratio of biotin to 
CS, and produces CS molecules that can be immobilized via one end, allowing the rest of 
the molecule to remain free to interact with proteins of interest. 
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Figure A1.7. Full-length expressed proteins bind to CS-E. 
 
 
After biotinylation, the concentrations of the biotinylated CS samples were 
determined by carbazole assay.25 The biotinylated CS-C or CS-E samples were then 
conjugated to streptavidin agarose beads, and cell lysates from COS-7 cells expressing 
NgR, p75, Lingo1, or PirB were incubated with the beads. The streptavidin-CS beads, and 
any proteins bound to the beads, were then pelleted and washed.  The bound proteins were 
eluted from the beads, and the eluates were analyzed by western blot for NgR-myc. This 
assay showed that CS-E (but not CS-C) is able to pull NgR out of solution, confirming that 
NgR binds preferentially to CS-E (Figure A1.7).  
The salt concentration of the lysis buffer, as well as the overall protein 
concentration, was critical for binding, as lysates diluted with water showed stronger 
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pulldown of NgR by CS-E, as compared with lysates diluted with phosphate buffered 
saline (PBS) or undiluted lysates (data not shown). The observed importance of salt 
concentration is consistent with previous results examining protein binding to 
glycosaminoglycans.26  
 
 
 
Figure A1.8. The CS-E monoclonal antibody (mAb) attenuates binding of CS-E polysaccharides to 
NgR-Fc.  NgR-Fc (400 nM) was added to microarrays alone or with the CS-E mAb (20 µM).   
 
 
 An important implication of these results is that blocking CS-E interactions may  
prevent the inhibition caused by CSPGs and promote axon regeneration. Our lab previously 
raised a monoclonal antibody against a pure synthetic CS-E tetrasaccharide,27 and 
experiments showed that the antibody generated in this manner was highly selective for the 
CS-E sulfation motif on polysaccharides, as measured by dot blot, ELISA, carbohydrate 
microarrays, and surface plasmon resonance.28 This antibody was able to block the 
interaction of CS-E polysaccharides with NgR on the array (Figure A1.8). 
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The microarray, SPR, and pulldown experiments show evidence that NgR and 
possibly other components of the receptor complex bind preferentially to CS-E. To 
determine if the NgR complex is in fact mediating the inhibitory signal of CS-E, we tested 
cerebellar granule neurons (CGNs) from p75 knockout (KO) mice to find if the inhibitory 
effect of CS-E would be attenuated in these neurons. Because NgR lacks an intracellular 
signaling domain and requires formation of a complex with the neurotrophin receptor p75, 
a receptor critical for the inhibitory activity of CNS myelin,8, 29, 30 we next investigated the 
contribution of p75 to CS-E activity. Mice lacking the p75 receptor have normal lifespans 
and are generally healthy, but lack sensation in their extremities and develop digital lesions 
as a result.31 We reasoned that p75 knockout mice would effectively lack a functional 
NgR/p75 receptor complex, as the NgR has no intracellular domain and thus depends on 
p75 to transmit its inhibitory signal. Neurons from either p75 -/- or wild-type control mice 
were cultured on substrates of poly-ornithine (P-Orn) alone or P-Orn coated with CS-E or 
CSPG for 24 h. We found that p75 -/- neurons do not display significant rescue on surfaces 
of CS-E or CSPG (Figure A1.9). This result may be explained by other proteins that can 
fulfill the role of p75 in the signaling complex, such as TAJ/TROY. 
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Figure A1.9. Neurite outgrowth inhibition mediated by CS-E and CSPGs is not significantly 
attenuated in p75NTR-deficient neurons.  CGN neurons from wild type or p75NTR-deficient mice were 
cultured on a substratum of P-Orn and CS-E or CSPGs.  Neurites were visualized by staining with 
an anti-βIII-tubulin antibody, and the percent neurite outgrowth is quantified relative to the wild-
type control.  Quantification from three experiments is reported. (n = 50-200 cells per experiment). 
 
 
Conclusions 
 
A major obstacle to axonal regeneration is the inhibitory environment encountered 
by injured axons. This activity is principally attributable to the myelin-associated inhibitory 
proteins and proteoglycans associated with the glial scar. The three proteins MAG, OMgp, 
and Nogo-66 account for the majority of myelin-based inhibition, and these proteins 
activate several receptor complexes, some of which are common to the different proteins. 
Several receptors for CSPGs have recently been identified, and these receptors engage the 
chondroitin sulfate component of CSPGs. The diverse sulfation patterns of CS have further 
complicated the study of these interactions, and our lab has focused on the CS-E motif 
which seems most responsible for the activity of CS.  
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Our binding results suggest that NgR may be the member of a receptor complex 
responsible for binding CS-E.  This means that NgR is a possible point of convergence for 
binding both groups of inhibitory molecules responsible from preventing neuronal recovery 
after injury in the CNS: the myelin inhibitory proteins and CSPGs. Recently, another group 
demonstrated that two variants of the NgR, NgR1 and NgR3, can serve as receptors for 
CSPGs.19 This supports our initial findings, and CS-E likely serves as the recognition 
element for NgR binding to CSPGs. Furthermore, our findings demonstrate that most of the 
ligands and receptors involved in myelin inhibition show preferred binding to the CS-E 
motif. As CS-E is upregulated during injury, this motif may act as a recruiting mechanism 
for these inhibitory molecules. Furthermore, this shared binding of the CS-E motif by the 
ligands and receptors may act as a mechanism to enhance the effect of binding. 
Genetic methods removing individual receptors have not been able to account for 
the inhibitory effect observed in vivo. Genetic removal of the receptors PirB or p75, which 
should remove receptors for both groups of inhibitory molecules, do not allow substantial 
growth past the injury site.32, 33 However, there may be an effect in certain systems and cell 
types, as deletion of the p75 receptor has been shown to allow recovery in the injured optic 
nerve.34 In the studies described here, p75-deficient neurons did not have enhanced growth 
capability of substrates of CS-E or CSPG.  
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Materials and Methods 
 
Microarray assays. Carbohydrate microarrays were generated by spotting 1 nl of the 
heparin (Sigma), hyaluronic acid (Sigma), dermatan sulfate (Sigma), heparan sulfate 
(Neoparin), chondroitin (Seikagaku) chondroitin sulfate (Seikagaku), or keratan sulfate 
(Seikagaku)  polysaccharide solutions onto poly-L-lysine-coated slides using a Microgrid II 
arrayer (Biorobotics; Cambridge, UK) at room temperature and 50% humidity. The 
concentrations of the solutions ranged from 500 nM to 20 µM, and were calibrated to one 
another using the carbazole assay for uronic acid residues.25 A given concentration of each 
polysaccharide was spotted ten times at different positions on the array. A boundary was 
created around the polysaccharide spots on the slides using a hydrophobic slide marker 
(Super Pap Pen, Research Products International) and the slides were blocked with 10% 
fetal bovine serum (FBS) in PBS with gentle rocking at 37 °C for 1 h, followed by a brief 
rinse with PBS. Human NgR-Fc, p75-Fc, or Fc control (R & D Systems) were reconstituted 
in 1% BSA in PBS, added to the bound region on the slides in 100 µl quantities at a 
concentration of 1-2 µM, and incubated at room temperature for 3 h. The slides were 
briefly rinsed three times with PBS, and then incubated with a goat anti-human IgG 
antibody conjugated to Cy3 (1:5000 in PBS) for 1 h in the dark with gentle rocking. After 
rinsing two times with PBS and once with H2O, the microarray was analyzed at 532 nm 
using a GenePix 5000a scanner, and fluorescence quantification was performed using 
GenePix 6.0. The experiments were repeated 5-6 times, and data representing the average 
of all spots (± SE, error bars) for all spots were shown.  
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Expression plasmids and cell lysis. Full-length human p75 cDNA (amino acids 1-427; 
Open Biosystems) was ligated into a pcDNA3 vector (Invitrogen), modified to fuse an HA 
tag to the 5’ end of the insert using the restriction enzymes NotI (N-terminal) and BamHI 
(C-terminal). Human NgR (amino acids 27-473; imaGenes) was ligated into a modified 
pAPtag-5 vector (GenHunter) which fuses a secretion signal sequence and a c-myc tag to 
the 3’ end of the insert using the restriction enzymes NotI (N-terminal) and BamHI (C-
terminal). Lingo-1 and PirB genes were subcloned from mouse cDNA (Open Biosystems) 
into a pCAX Myc6 vector using the restriction enzymes HindIII (N-terminal) and XhoI (C-
terminal) to place an N-terminal 6X Myc tag on the expressed proteins. The vector 
contained a secretion peptide coding sequence upstream of the myc tag; thus, the 
endogenous signal peptide coding sequences were excluded from the cloning sequence.  
 
p75 sense primer: 
GTGGCGGCCGCCATGTATCCATATGATGTTCCAGATTATGCTATGGGGGCAGG
TGCCACC 
p75 antisense primer: 
GCGGGATCCTCACACCGGGGATGTGGCAGTGGACTCACTGCACAGACTCTCCA
CG 
 
NgR sense primer: GTGGCGGCCGCCATGAAGAGGGCGTCCGCTGGAGGGAGC 
NgR antisense primer: 
GCGGGATCCTCACAGATCCTCTTCAGAGATGAGTTTCTGCTCGCAGGGCCCAA
GCACAGTCC 
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Lingo-1 sense primer: CCCAAGCTTACACGGGCTGCCCGCCCCGCTGCGAG 
Lingo-1 antisense primer: CCGCTCGAGTATCATCTTCATGTTGAACTTGCG 
 
PirB sense primer: CCCAAGCTTACTCCCTCCCTAAGCCTATCCTCAGA 
PirB antisense primer: CCGCTCGAGTTGCTCCATGTCCTTGGGAACAGC 
 
COS-7 cells were transfected using the Lipofectamine (Invitrogen) method. Cells were 
lysed two days after transfection with 1% Triton X-100 in PBS containing a protease 
inhibitor mixture (Roche) by rocking for 30 min at 4 °C. The lysates were clarified by 
centrifugation at 13,000 rpm for 5 min. 
 
CS biotinylation. Biotin was attached to the free amino group of the residual core peptides 
of CS-C and CS-E polysaccharides (Seikagaku) with minor modifications to Saito et al.24 
Briefly, CS-C and CS-E (2 mg each) were dissolved in 1 ml of 0.05M NaHCO3 for 30 min 
at room temperature. EZ-Link Sulfo-NHS-LC-LC-Biotin (0.25 mg; Pierce) was dissolved 
in 1 ml of H2O and added to each CS sample. The solution was mixed at room temperature 
for 3 h, lyophilized, resuspended in H2O, and subjected to gel filtration using Sephadex G-
50 (Amersham) to remove excess biotin.  
 
Pull-down assays with biotinylated CS. Biotinylated CS-C and CS-E (280 µg each) in 
300 µl of PBS were added to 140 µl of settled streptavidin agarose resin (Pierce), and 
incubated at room temperature for 1 h. The supernatant was removed and the resin was 
washed twice with 500 µl PBS to remove unconjugated CS. Clarified COS-7 cell lysates 
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were diluted 1:10 with PBS, and further diluted 1:2 with H2O. Diluted lysate (500 µl, 0.8 
mg/ml total protein) was incubated with 30 µl of unconjugated streptavidin agarose resin 
with mixing for 1 h at 4°C. The supernatant was collected, added to 30 µl of either CS-C or 
CS-E streptavidin agarose resin, and incubated with mixing for 4 h at 4°C. The supernatant 
was removed, and the resin was washed three times with 500 µl PBS. Resin was boiled 
with 30 µl 2X loading dye (100mM Tris, 200mM DTT, 4% SDS, 0.10% bromophenol 
blue, 20% glycerol) and the eluates were collected and separated by SDS-PAGE. NgR-
myc, Lingo-1-myc, PirB-myc, and p75-HA were detected by immunoblotting with 
monoclonal myc-tag (Cell Signaling) or HA-tag (Sigma) antibodies. 
 
CGN neurite outgrowth assays.  Nitric acid-treated, 15-mm round German glass 
coverslips were coated with P-Orn in borate buffer, pH 8.5 (50 µg/ml) for 1 h at 37 °C and 
5% CO2.  CSPGs (1 µg/ml) or polysaccharides enriched in the CS-A, CS-C, or CS-E 
sulfation motifs (1 µg/ml) were coated on the P-Orn-coated coverslips overnight at 37 °C 
and 5% CO2. For neurite outgrowth experiments from p75 knockout mice, cerebella from 
P5-7 mice, either C57BL/6 wild-type or p75-/- knockout mice, were dissected, incubated in 
0.125% trypsin w/ EDTA for 10 min at 37 °C, triturated to dissociate to single cell 
suspensions, purified on discontinuous 35%/60% Percoll gradient, and cultured on the 
coated coverslips in Neurobasal medium supplemented with B27, GlutaMAX™ 
(Invitrogen), and 40 ng/ml bFGF (R&D) at a density of 200-300 cells/mm2 for 24 h. Cells 
were fixed in 4% PFA with 10% sucrose, immunostained using an anti-β tubulin III 
antibody (TUJ1; Covance), imaged using a Nikon TE2000-S fluorescent microscope and 
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quantified using the NIH software ImageJ. Statistical analysis was performed using the 
one-way ANOVA; n = 50–200 cells per experiment, and results from at least three      
independent experiments were reported.
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